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 7  
Background 
 
Treatment of end-stage organ failure by organ transplantation has significantly 
improved over the past 50 years. The necessary surgical skills, peri-operative 
management and adequate suppression of the immunological response against 
the allograft have all significantly contributed to better outcomes. In the 1960s and 
1970s organ transplantation gained considerable interest and the rate of successful 
transplantation slowly increased with the use of immunosuppressants such as 
azathioprine and corticosteroids(1). The introduction of Cyclosporin A (CsA), 
however, showed adequate suppression of the immunological response and 
revolutionized allograft transplantation. With the use of CsA the one year graft 
survival rates of renal transplant recipients increased to over 80 percent and made 
transplantation of the lung, heart, liver, pancreas, hand, and kidney, feasible in 
clinical practice as life-saving or life-prolonging therapy(1). Since then, several 
other small molecule drugs and protein (antibody) preparations, have been 
developed and used as immunosuppressive agents(2). These new drugs have led 
to a further decrease of organ rejection episodes, but unfortunately long term 
allograft survival rates have not improved to the same extend over the past 
decades(3). These data directly points towards one of the major issues associated 
with current immunosuppressive protocols in renal allograft recipients; drug related 
toxicity and/or over-immune suppression that compromise long-term success. 
Individualization of the immunosuppressive therapy by tailor-made 
immunosuppressive protocols is considered a key strategy to further improve long-
term graft survival. This means that the immunosuppressive regime and dosing are 
adjusted to the biological variance between individuals. Monitoring of drug 
exposure by therapeutic drug monitoring (TDM) is now routinely applied for most 
immunosuppressive drugs and at the present individual drug exposure is controlled 
by regular assessment of blood drug concentrations. Since large variation in 
pharmacokinetics of immunosuppressants has been observed and most drugs 
have only a small therapeutic window, better control of drug bioavailability has 
further improved therapy outcome(4). Nevertheless individualization is still 
warranted and several new strategies such as pharmacogenetics and 
pharmacodynamics are currently investigated. Pharmacogenetic parameters may 
predict the pharmacokinetic profile of individual subjects and guide initial dosing to 
achieve therapeutic target ranges as soon as possible(5). Pharmacodynamic 
monitoring strategies hold the promise to measure drug effectiveness parallel to 
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pharmacokinetic parameters and may provide additional information to define new 
therapeutic target conditions.     
 
 
Molecular mechanisms of allograft rejection  
 
Allograft recognition 
Allograft rejection is the recognition of the transplanted tissue as being non-self, 
followed by specific targeting of the allograft by the host’s immune system. Key 
molecules involved in the process of recognizing non-self epitopes are the major 
histocompatibility complex (MHC) proteins. These proteins can be divided into two 
classes; Class I molecules that are expressed on most cells and present peptides 
from endogenous proteins, and Class II molecules that have a more restricted 
distribution and are generally associated with the presentation of peptides from 
exogenous proteins(6). Cells that express MHC class II proteins are assigned as 
antigen presenting cells (APCs). Both MHC class molecules are highly 
polymorphic, especially at sites that determine the peptide binding groove. These 
differences can directly evoke immune responsiveness of host cells(6). This is 
observed in hyperacute rejection when preformed antibodies against HLA class I or 
ABO blood group system are present in the circulation or lymphatic structures of 
the recipient. It is found that peptides from MHC molecules themselves are 
prominently presented by MHC molecules. It is therefore thought that a major 
contribution to allo-recognition via MHC molecules is mediated via presentation of 
peptides from MHC molecules on either donor (direct) or host (indirect) MHC 
proteins(6).  
For successful allo-recognition, adequate T cell receptor (TCR) binding of 
allogeneic MHC in the context of co-stimulatory signals is required. A requirement 
for TCR binding is its association with the CD3 complex that allows surface 
expression of TCRs and signal transduction following antigen recognition. Other T 
cell molecules involved in T cell recognition are the CD4 or CD8 proteins. These 
proteins cross-link either MHC I (CD8) or MHC II (CD4) and play key roles in 
allowing T cell responsiveness, especially when the affinity of TCR for MHC is 
low(6). TCR binding itself is insufficient for activation of the T cell and without co-
stimulatory signaling, TCR binding leads to anergy(7). For successful T cell 
activation, a second signal is required that exist of a non-antigen driven interaction 
between antigen presenting cell and T cell(7). The most potent but not crucial co-
stimulatory molecules known are B7s (CD80/86) that are presented by APCs and 
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interact with CD28 on T cells(8). When allo-antigen specific T cell clones are 
successfully activated, biochemical changes are induced that allow transcription of 
response genes such as cytokines and surface proteins that are involved in 
controlling adhesion to APC, target and other (immune) cells, endocrine/paracrine 
signaling and clonal expansion of the activated T cell clones.  
 
T cell activation 
Intracellular T cell activation responses are initiated by the activation of the TCR, 
which leads to activation of tyrosine kinases such as LCK and ZAP70 that 
phosphorylate several substrates such as SLP76 and LAT(9). These proteins 
recruit and activate other proteins such as phospholipase Cγ. Phospholypases 
catalize the hydolysis of the membrane phospholipid phosphatidylinositol-1,4,5-
biphosphate to inositol-1,4,5-triphosphate (IP3) and diaglycerol (DAG)(9). IP3 binds 
to IP3 receptors on the endoplasmatic reticulum that result in the release of Ca
2+
 
into the cytosolar cell compartment. This initial release of Ca
2+
 itself is not sufficient 












 signaling results in the activation of transcription factors such 
as NFAT. Only sustained Ca
2+
 levels allow prolonged NFAT translocation and 
NFAT-dependant gene transcription(9;10). 
The Ca
2+
-NFAT signal transduction is mediated via calcineurin. Calcineurin (CN) is 
the Ca
2+
 and calmodulin dependant serine-threonine protein phosphatase, which 
becomes activated by an increase of intracellular Ca
2+
(11). The cytosolic NFAT 
proteins are dephosphorylated by CN at serines within the N terminus of the SP 
repeats and the serine-rich region(10). Dephosphorylation of these serines is 
thought to expose nuclear localization sequences, resulting in rapid NFAT 
translocation to the nucleus(10). Upon co-stimulation, NFAT interacts with 
members of the AP-1 protein to form a transcription complex that is essential for a 
productive immunological response(7). The NFAT AP-1 transcription complex 
transcribes a large number of genes encoding cytokines (e.g. IL-2, IL-4, IFNγ), 
chemokines (e.g. GM-CSF) and surface proteins (e.g. CD40L, IL2Rα) that activate 
and control the immunological T cell responses(12). The CN inhibitors tacrolimus 
and cyclosporine block T cell activation by inhibition of CN phosphatase activity 
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Calcineurin and its isoforms 
 
CN is the serine-threonine-specific, Ca
2+
/ calmodulin dependant protein 
phosphatase and composed of a 59 kDa catalytic subunit also referred to as CN A 
and a 19 kDa regulatory subunit also referred to as CN B(13).  CN A contains a 




, a CN 
B-binding helical domain, a calmodulin binding domain and an auto-inhibitory 
domain(14). This autoinhibitory domain forms a loop that covers the active site in 
the unligated CN structure. CN B consists of two globular Ca
2+
-binding domains 
that have two Ca
2+
-binding EF hand motifs and are similar to those of 
calmodulin(14). Ca
2+
/ calmodulin binding to the corresponding binding domain 
reverses the self-inhibition by inducing conformational changes in the protein 
structure, resulting in exposure of the active site(15).  
 
Figure 1.1. Ribbon diagram of calcineurin. Gold is calcineurin A, blue is calcineurin B, green is the 






 respectively. BBH is 
the calcineurin B binding domain, CNA is Calcineurin A, CNB is Calcineurin B(14). 
 
Three different CN A isoforms (α, β and γ) have been described(13). The 
expression of CN Aγ is restricted to testis and specific parts of the brain, while the 
CN Aα and CN Aβ isoforms are present in all tissues examined(13). The overall 
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amino acid sequences of CN Aα and CN Aβ are 81% identical, while the sequence 
identity within the catalytic region, the CN B binding helix, the Ca
2+
/calmodulin-
binding domain and the auto-inhibitory domain is 90%(16). Variations in the 
amount and ratio of CN Aα : CN Aβ have been identified within and between 
tissues. In brain, CN Aα is more abundant than CN Aβ. CN Aα is more abundant in 
kidney and its expression is largely restricted to the tubules, while CN Aβ 
expression was observed mainly in the glomerular region(13;17).  
In T and B cells, CN Aβ is more abundant(17). Interestingly small differences in 
kinetic profiles are observed(18). Also differences in physiological roles have been 
identified, and the absence of CN Aα, but not CN Aβ, fous found to be responsible 
for a defect in normal maturation of the nephrogenic zone and glomeruli, alterations 
in the cell cycle and impaired kidney function(19).  
In mammals two different CN B genes have been identified. One is ubiquitously 
expressed (CN B1)(13;20), and gene transcripts for the second gene (CN B2) are 




Calcineurin; function and pathogenesis of malfunction 
 
Neuronal tissue 
CN is probably best known as rate limiting step in T cell activation, but its 
expression in many tissues and different cell types indicates an important role in 
many physiological control mechanisms. The highest levels are found in the brain 
and its localization in neuronal tissue together with its Ca
2+
-binding properties was 
the basis for its descriptive name “calcineurin”, introduced by Klee et al.(22). CN 
has several substrates that are located in neuronal tissue including dynamin 1, 
synapsin 1, Myristoyoated alanine-rich C-kinase substrate, neuromodulin and 
neurongranin.  
Dynamin 1 is a neural phosphoprotein and a GTPase that mediates late stages of 
endocytosis in both neural and non-neural cells(23). High concentrations of 
intracellular calcium causes association between CN and dynamin 1 as well as the 
dephosphorylation of dynamin 1 and the delivery of CN to the endocytic protein 
complex enabling CN to initiate dephosphorylation of other proteins(24). 
Synapsins are the most abundant vesicle proteins, synapsin 1 alone accounts for 
approximately 6% of total vesicle protein(25). Under resting conditions synapsins 
tether synaptic vesicles to cytoskeletal elements and prevent neurotransmitter 
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release, while during synaptic activity synapsins are phosphorylated, dissociate 
from synaptic vesicles and allow vesicles to mobilize and fuse with the plasma 
membrane(25). CN inhibition by CsA completely blocked dephosphorlyation of 
certain phosphorylation sites on synapsin 1 that resulted in a prominent increase of 
the neurotransmitter glutamate(26).  
Other substrates of CN are neuromodulin (B50, F1, GAP43), which is localized 
within axonal membranes of neurons and is believed to play a role in the 
modulation of membrane signal transduction and axonal regeneration, neurogranin 
(RC3, p17), which is thought to serve as a "third messenger" substrate of the PKC-
mediated pathway during synaptic development and remodeling and myristoyoated 
alanine-rich C-kinase substrate (MARCKS). MARCKS is implicated in the 
mechanisms of membrane trafficking and regulation of the cell cycle and it has 
been reported that phoshporylation of MARCKS plays an important role in release 
of neurotransmitters, such as noradrenaline and serotonin and 
adrenocorticotropin(27). It is thought that CN reverses protein kinase C induced 
actions of these proteins(27).  
Since CN is important for adequate neuronal functioning, treatment with CN 
inhibitors may induce severe neurotoxicity resulting in headaches, altered mental 
status, seizures, cortical blindness, auditory and visual hallucinations, spasticity, 
paresis and ataxia(28).  
CN has also been associated with the pathogenesis of Alzheimer’s disease. One of 
the hallmarks of Alzheimer’s disease is aggregation of hyperphosphorylated tau to 
neurofibrillary tangles in affected neurons(29). Phosphorylation of tau is controlled 
by tau kinases and phosphatases and it is thought that abnormal tau 
hyperphosphorylation might be due to defective phosphatase activity(29). CN is an 
important tau phosphatase and it has been suggested that defective CN activity 




Two regulators of actin functioning, calponin and cofilin, are substrates of CN. The 
first is a smooth muscle-specific, thin filament-associated protein, which has been 
implicated in the regulation of contraction via its interaction with actin and inhibition 
of the cross-bridge cycling rate. Phosphorylation of calponin causes loss of actin 
binding and inhibition of the actin-activated myosin MgATPase(31). Cofilin is an 
essential regulator of actin filament dynamics that is inactivated by phosphorylation 
and reactivated by dephosphorylation. It is thought that a CN-dependant 
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dephosphorylation pathway is responsible for dephosphorylation and thus 
activation of cofilin(32).  
CN is also associated with cardiac hypertrophy a mechanism that was found to be 
dependant on subtypes of the NFAT transcription family(33). In addition, transgenic 
mice over-expressing CN showed a profound hypertrophic response that rapidly 
progressed to dilated heart failure(34).   
 
Renal tissue 
In renal tissue, calcineurin is a central regulator of calcium-mediated signaling. It is 
associated with the regulation of factors that are of particular importance in renal 
physiology such as TGFβ and IGF-I(19). The most illustrative evidence of the 
relevance of CN activity in the kidney is however the pronounced nephrotoxicity of 
the selective CN inhibitors TRL and CsA resulting in tubulointerstitial fibrosis and 
tubular atrophy(19;35).  
In renal tissue, CN A isoforms seems to have distinct functions. Mice lacking CN 
Aα, reproduced the characteristics of CN inhibitor nephrotoxicity, while CN Aβ -null 
mice did not. In vitro experiments showed that NFATc translocation was specifically 
regulated by the CN Aβ isoform, whereas CN Aα regulated fibronectin and TGFβ 
expression(36). 
 
Regulation of NFAT transcription 
Probably the best know substrates of CN are the Nuclear Factor of Activated T 
Cells (NFAT) transcription factors. The family of NFAT transcription factors consists 
of 5 members; NFAT1 (NFATp, NFATc2), NFAT2 (NFATc, NFATc1), NFAT3 
(NFATc4), NFAT4 (NFATx, NFATc3) and NFAT5. NFAT1-4 are regulated by 
CN(12). Dephosphorylation of serines at the amino terminal regions of these NFAT 
proteins exposes nuclear localization sites that lead to rapid nuclear translocation. 
In immune cells co-operation with other transcription factors such as AP-1 leads to 
lymphocyte activation and the transcription of cytokines such as IL-2, IL-4, IFNγ, 
TNFα and many more(11). NFAT self in absence of co-stimulatory signaling can 
induce a different set of anergy-associated genes that mediate T cell anergy(12). 
Next to lymphocyte functioning, the calcineurin/NFAT pathway was found to be 
important in the development and functioning of the cardiovascular system(10), 
musculoskeletal system(10), perinatal lung(37) and pancreatic β-cells (38), glucose 
and insuline homeostasis(39), regulation of bone mass in osteoclasts and 
osteoblasts(40) and the pathogenesis of leukemia(41;42).    
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Regulators of calcineurin 
Several endogeneous proteins are known that control CN activity. One is AKAP79 
scaffold protein that seems to prevent CN's access to substrates(10). A second 
inhibitor is cain (cabin-1), that blocks CN activity(43), a third a CN B homolog 
named CN homologous protein (CHP), that binds to CN A but is not able to induce 
its activation(44). The last endogenous inhibitor of CN identified is MCIP1 
(myocyte-enriched CN interacting protein 1 (also referred to as calcipressin / 
DSCR1 (Down Syndrome Critical Region 1) / Rcn1)(45), DSCR1L2 and ZAKI-
4(46). It is suggested that DSCR1 functions as a feedback inhibitor of CN, since 
DSCR1 expression is induced by calcium through a CN-dependant mechanism. 
This loop might be necessary to avoid sustained CN activity in situations of 
prolonged Ca
2+
 stimulus(46).  
An important role of this protein is suggested in the pathogenesis of Down’s 
syndrome(47). Here the trisomy of a part of chromosome 21 that is present in 
individuals suffering from Down’s syndrome contains DSCR1 and DSCR1 is 
expressed 1.5 times higher that normal. This increase in DSCR1 is thought to 
destabilize normal regulatory systems of the CN-NFAT pathway. This deregulation 
of the CN pathway may explain many of the developmental and regulatory features 
of Down’s syndrome(47).   
Besides endogenous proteins also some exogenous proteins inhibit CN activity. 
Some viruses mitigate immune responses by inhibiting CN/NFAT signalling. For 
instance the A238L protein of the African swine fever virus binds directly to CN, but 
also other microorganisms as diverse as Trichoderma, Streptomyces and 





There are several inhibitors of CN but many are not specific for CN protein 
phosphatase and lack high affinity. Examples of these are okadaic acid (IC50 ± 4 
µM), microcystin LR (IC50 ± 200 nM)(13). An example of a selective CN inhibitor is 
5-dibenzoyloxymethyl-substituted norcantharidin (IC50 = 50 µM) that was 
computationally designed and shows no inhibition of protein phosphatases 1 and 
2A(48).  
Inhibition of CN by exogenous molecules is most specific by interaction with 
immunophilin families. There are two structurally distinct immunophilin-
immunosuppressant families that show CN inhibition: Cyclophilin A-Cyclosporin A 
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(CsA) and FKBP (FK506 Binding Proteins)-FK506 (Tacrolimus, TRL) (49;50). Both 
complexes have a large overlap in CN interaction sites and bind to the same 




Figure 1.2. Ribbon diagram of immunophilin-immunosuppressant interaction with calcineurin. 




Cyclosporine A (CsA) was originally isolated from the fungus Cylindrocarpon 
lucidum and identified as antilymphocytic agent during a screening program at 
Sandoz (now Novartis). It was found that CsA differed from the then known 
immunosuppressive agents in that a low degree of myelotoxicity was observed and 
was identified as the first immunosuppressive agent with more specific anti-T cell 
activity(51).  
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CsA consists of a cyclic peptide consisting of 11 amino acids with a molecular 
weight of 1202.6 Da(51). Seven of its amino acids are methylated and there is one 
unique aminoacid that contains a N-methyl-(4R)-4-butenyl-4-methylthreonine, see 
Figure 1.3.  
 
Figure 1.3. Molecular structure of cyclosporin A(55) 
 
Cyclosporine A pharmacokinetics 
From the moment the standard oil-based formulation of CsA (Sandimmune) was 
introduced into clinical practice in the early 1980s, CsA therapy was characterized 
by poor and unpredictable absorption(52). This was caused by gastrointestinal 
water-droplets that are formed after oral administration that required emulsification 
for the release of CsA and made the absorbance of the drug dependant on food 
intake, bile flow and gastrointestinal motility(52). To overcome these issues, a new 
micro-emulsion preconcentrate formulation of CsA was developed that ensured 
independence of bile flow for emulsification and resulted in higher, faster and less 
variable absorbance of CsA(52). Another factor that significantly affects 
absorbance of CsA is the drug exporting activity of the enterocytes by the ATP 
binding cassette protein para-glycoprotein (pgp). Pgp actively pumps CsA back into 
the gut lumen and reduces its absorbance(53).  
After intestinal absorption, most cyclosporine leaves the bloodstream and is 
concentrated in leukocyte-rich and fat-rich organs(54-56). Within the blood, CsA is 
highly bound to the erythrocytes (60-70%), lipoproteins and leukocytes (9%) 
resulting a low free fraction of only 1-1.5%(55;57). 
The main metabolizers of CsA are the CYP3A4 and CYP3A5 members of the 
cytochrome P450 mixed function oxidase system and around 30 metabolites have 
been identified that all preserve the cyclic structure of CsA(57). Since many drugs 
are either substrates, inhibitors or inducers of the CYP 3A4/5 enzymes, 
pharmacokinetic drug-drug interactions at this level can significantly effect the 
metabolization and clearance of CsA(58). The average half life of CsA is about 19 
hours and CsA is excreted over 90% in bile of which less than 1% is unaltered. 6% 
is excreted by urine of which only 0.1% is unaltered(55).  
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Tacrolimus 
In the course of a search for new immunosuppressive agents in the Fujisawa 
laboratories in 1982, a strain of  streptomyces tsukubaensis No. 9993 was found to 
produce a potent immunosuppressive agent now designated as FK506(59). FK506 
is a neutral macrolide that is insoluble in water, slightly soluble in saturated 
hydrocarbons and highly soluble in lipids and other organic solvents(55). The name 
tacrolimus, derived from Tsukuba macrolide immunosuppressant, was assigned to 
the compound(60). Its chemical structure consists of a 23-member ring and is 
shown in Figure 1.4(61).  
 
         
Figure 1.4. Molecular structure of tacrolimus(55) 
 
Tacrolimus pharmacokinetics 
Tacrolimus (TRL) is traditionally formulated in the twice daily (Prograft
®
) 
formulation, although recently a new once daily formulation was introduced 
(Advagraft
®
)(62). The bioavailability of TRL is poor (mean around 25%) and highly 
variable; it ranges from 4 to 89% in renal, and liver allograft recipients(63). In blood, 
TRL is highly distributed to the erythrocyte fraction and most of the drug in human 
plasma is bound to plasma proteins(63). It was found that the drug content per cell 
is higher in leukocytes and that the drug distribution in blood depends on drug 
concentration, temperature and hematocrit values(64). TRL is primarily 
metabolized by the CYP3A subfamily and over 15 metabolites have been 
identified, some of which showed pharmacological activity(63;65). Less than 1% of 
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TRL is excreted unchanged and biliary excretion of TRL metabolites is the major 
pathway of TRL body clearance(63).  
 
Therapeutic monitoring of calcineurin inhibitors 
Calcineurin inhibitor (CNI) treatment is associated with significant side effects such 
as nephrotoxicity, neurotoxicity and hypertension. These side-effects are observed 
at therapeutic concentrations resulting in a narrow therapeutic index for both CsA 
and TRL. Since the pharmacokinetics of CsA and TRL are highly variable, 
controlling of drug exposure by means of therapeutic monitoring is mandatory. The 
golden standards for controlling CNI treatment is measurement of through blood 
concentration (C0). Unfortunately, C0 doesn’t correlate well to total drug exposure. 
Peak concentration measurement shows a better correlation with total drug 
exposure and is therefore also applied(66). Since CNI generally peak 2 hours after 
drug intake drug concentration measurement at 2 hours after drug intake (C2) is 
performed. Unfortunately in the case of slow absorbers, e.g. diabetic patients, the 
maximum CNI concentrations are found at later time points. There is also a danger 
that drug exposure in fast metabolizers is overestimated, e.g. CYP3A5 genotype 
recipients. These cases are estimated to constitute 20% of the renal 
transplantation population. Advanced pharmacokinetic monitoring such as by 
estimated AUC could detect such cases and allow proper dosing for these 
individuals(67). When advanced pharmacokinetic population models are applied, 
anticipation on small deviations from the standardised sampling and drug intake 
times is possible. 
Whole blood concentrations are currently used as surrogate for effect. 
Unfortunately, whole blood concentrations of CNI do not necessarily correlate to 
intracellular concentrations. CNIs are highly distributed to the erythrocyte fraction 
and bound to lipoproteins. Variation in these concentrations changes the 
distribution of CNIs in whole blood(68;69). Also the expression of drug efflux 
transporters such as para-glycoprotein on target cells (T cells) can theoretically 
effect the cellular distribution for both TRL and CsA(70). In addition, the 
immunological response of CNI is much more complicated that just drug 
concentration measurement; sub-cellular distribution of the CNIs could be an issue, 
CNI require immunophilins for their pharmacological action and immunological 
drug-drug interaction with other immunosuppressive agents can be expected. To 
overcome these variables, measurement of drug effect is at least in theory a more 
accurate alternative and should better reflect the actual immunosuppressive state 
induced by CNIs(71;72). Insights in individual CNI effectiveness together with their 
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pharmacokinetic parameters could therefore, in theory, allow a more tailored 
dosing regime resulting in better CNI performance.    
Efforts are made to monitor immunosuppressive effectiveness of CNIs on the level 
of target enzyme activity, transcripts and cytokine/ surface receptor expression. All 
show clear drug concentration vs. effects relations, but could not explain the large 
inter-individual variation of the markers by relevant clinical endpoints such as acute 
rejection thus far. Therefore further investigation and understanding of the potential 
of these techniques for monitoring and control of CNI treatment is very valuable. In 
this thesis the potential of CN activity as pharmacodynamic marker for monitoring 
CNI treatment is investigated. 
 
 
Scope/Outline of this thesis 
 
This thesis constitutes a comprehensive investigation into the analytical variables, 
fundamental concepts and clinical application of CN activity measurement as 
pharmacodynamic marker for CN inhibition therapy. First an assay for 
measurement of CN enzyme activity was developed and validated for its analytical 
performance (Chapter 2). To gain insights in the potential of CN activity as 
pharmacodynamic marker, CN inhibition, T cell cytokine excretion and their relation 
was investigated at therapeutic CsA concentrations (Chapter 3). Next, blood 
sample was investigated in order to optimize sample choice (Chapter 4). Since it 
was found that variable sample composition could affect measurement outcome 
and T cells are the major site of action of the CN inhibitors, a T cell specific 
calcineurin assay protocol was developed and validated as a novel 
pharmacodynamic monitoring tool for CsA therapy (Chapter 6).  
To gain further insights in the opportunities and hurdles for pharmacodymic 
strategies of CN inhibition therapy we performed a literature review (Chapter 5). To 
elucidate potential new applications of pharmacodynamic monitoring tools the 
pharmacological and immunological drug-drug interaction between mTOR 
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The calcineurin inhibitors, cyclosporine and tacrolimus, still constitute the 
cornerstone of immunosuppressive regimen after organ transplantation. An 
efficient and feasible way to measure calcineurin activity and inhibition by these 
drugs may improve therapeutic monitoring of these drugs in transplant recipients. 
Calcineurin activity was measured in leukocyte lysates isolated from human blood 
using spectrophotometric phosphate quantification. The dephosphorylation of a 19-
amino acid peptide substrate of calcineurin was determined using the Malachite 
green phosphate reagent in the presence of okadaic acid and with and without the 
calcium chelator EGTA. Sample storage and lysis buffer components were among 
the variables optimized, and the inhibitory effect of calcineurin inhibitors was 
investigated.  Observed loss of calcineurin activity during sample storage was 
eliminated by adding ascorbic acid to lysis buffer. The final inter- and intraassay 







, where WBC is white blood cells (leukocytes). In vitro 
IC50 values were 212 and 34 µg/L for cyclosporine and tacrolimus, respectively. In 
vivo calcineurin inhibition was observed when calcineurin activity was measured in 
transplant recipients on maintenance therapy with cyclosporine and tacrolimus. 




A quarter-century ago, the launch of the fungal cyclic undecapeptide cyclosporin A 
(CsA) as a maintenance immunosuppressant revolutionized organ transplantation. 
This was followed by the introduction of the structurally unrelated but 
mechanistically similar drug tacrolimus (TRL) and a microemulsion formulation of 
CsA with a more predictable absorption profile. Both drugs are inhibitors of the 
calcium-dependent protein phosphatase calcineurin (CN) that ultimately regulates 
lymphocyte activation-associated cytokine production by dephosphorylation of the 
nuclear factor of activated T cells(1–3). Despite the marked improvement in acute 
rejection rates, unfavorable cardiovascular profile and nephrotoxic potential of CsA 
and TRL question the long-term applicability of these drugs(4). The balance 
between the prevention of acute rejection episodes and the chronic toxicity 
associated with high concentrations of these drugs is critical and is described as a 
narrow therapeutic index. Trough blood calcineurin inhibitor (CNI) concentration is 
routinely used for therapeutic drug monitoring of CNIs; however, correlation with 
clinical outcome is unsatisfactory, and cases of acute rejection and chronic 
nephrotoxicity remain(5). Many attempts are being made to improve this 
pharmacokinetic monitoring via the use of area under the curve (AUC) models(6) 
and samples taken 2h after drug administration(5,7). The use of a 
pharmacodynamic parameter to quantify the intracellular inhibitory effect of the 
CNIs has been proposed(8), and the first pharmacodynamic analyses of CNIs in 
transplantation patients have been published(9–13).  
Most current techniques that attempt to measure CN phosphatase activity in 
clinical samples monitor the Ca
2+
-dependent dephosphorylation of a 
phosphopeptide substrate derived from the RII subunit of protein kinase A(10–
12,14–16). Many groups refer to the method published by Fruman and coworkers 
that involves an isotopic form of this peptide substrate and chromatographic 
separation and measurement of the 
32
P-labeled phosphate product(17). Another 
technique, published by Enz and coworkers, uses HPLC to separate and quantify 
the phosphorylated substrate and dephosphorylated product(18).  
We aimed to develop a more rapid and feasible CN assay that can be used to 
measure CN activity routinely in a clinical setting. As a result, we present a new 
protocol involving a nonradioactive spectrophotometric-based phosphate detection 
assay that has been optimized to enable monitoring of CN phosphatase activity 
and its inhibition by the immunosuppressants CsA and TRL in leukocytes isolated 
from human blood. 
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Materials and Methods 
 
Materials 
The following materials were used: dithiothreitol (DTT), ascorbic acid, Nonidet P40 
(NP-40), and soybean trypsin inhibitor from Sigma–Aldrich (Steinheim, Germany); 
phenylmethylsulfonyl fluoride from Merck (Darmstadt, Germany); leupeptin from 
Roche (Basel, Switzerland); aprotinin from Bayer (Leverkusen, Germany); 
phosphate standard concentrate from Fluka (Buchs, Switzerland); CsA 
microemulsion formulation from Novartis (Basel, Switzerland); and TRL from 
Fujisawa (Munich, Germany). The assay buffer, ethyleneglycoltetraacetic acid 
(EGTA) buffer, calmodulin, recombinant CN, okadaic acid, Malachite green 
reagent, and RII phosphopeptide substrate were obtained from the Biomol Green 
Cellular Calcineurin Assay Kit PLUS purchased from Biomol (Plymouth Meeting, 
PA, USA). All other chemicals and reagents were of the highest available grade.  
 
Blood collection  
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated blood from the anticubal 
veins of healthy volunteers was used for assay optimization and validation 
experiments. In addition, EDTA anticoagulated blood from the anticubal veins of 
patients on CsA and TRL maintenance therapy following kidney transplantation 
was used to study in vivo CN inhibition. Four patients (two males and two females) 
received CsA (100–125 mg twice a day [BID]) as 
part of their immunosuppressive therapy, and four other patients (three males and 
one female) received TRL (2–4 mg BID) as part of their immunosuppressive 
therapy. The CsA-treated patients (ages 25–61 years) had undergone 
transplantation 3 months before, and the TRL-treated patients (ages 27–68 years) 
had undergone transplantation 6 months to 3 years before. Blood was taken 
immediately prior to drug intake (C0) and 2 h after drug intake (C2). From one 
patient on CsA (63-year-old male, 7 days after transplantation, 250 mg CsA BID) 
and one patient on TRL (47-year-old female, 7 days after transplantation, 6 mg 
TRL BID), blood was collected at multiple time points after drug intake.  
Formal approval from the institutional ethics committee was obtained at the 
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Preparation of total leukocyte lysates  
Leukocyte lysates were prepared at 4°C from fresh blood and always within 24 h 
after sampling. To remove erythrocytes and platelets, 2.5 ml blood was added to 
37.5 ml NH4Cl lysis buffer (8.4 g/L NH4Cl and 1.0 g/L KHCO3, pH 7.3) and was 
incubated on ice for 10 min with inversion every 2 min. Intact leukocytes were spun 
down (350g, 10 min, 4°C), and supernatants containing erythrocyte and platelet 
lysates were discarded. Cell pellets were washed twice in 10 ml Hepes-buffered 
saline (9.0 g/L NaCl and 10 mM Hepes, pH 7.5), spun down (350g, 10 min, 4°C), 
and then resuspended in 1.5 ml Hepes-buffered saline. A 250-µl aliquot was taken 
for a leukocyte count performed on a Sysmax XE2100 (Mundelein, IL, USA), and 2 
million leukocytes were aliquoted per microcentrifuge tube and were spun down 
(500g, 10 min, 4°C). Supernatants were removed, and leukocytes were 
resuspended in 200 µl lysis buffer (50 mM Tris–HCl [pH 7.7], 1.0 mM DTT, 5.0 mM 
ascorbic acid, 0.02% [v/v] NP-40, 50 mg/L soybean trypsin inhibitor, 50 mg/L 
phenylmethylsulfonyl fluoride, 5.0 mg/L leupeptin, and 5.0 mg/L aprotinin) and were 
lysed by three freeze–thaw cycles (liquid N2/30°C). Cell debris was spun down 
(10000g, 10 min., 4°C), and supernatant was collected. Lysates were snap-frozen 
in liquid N2 and stored at -80°C until they were assayed for CN activity. 
 
CN activity assay 
Two phosphate quantifications were performed per sample using a 96-well plate 
(half area, Costar, Corning): one in the presence of EGTA and the second in the 
presence of Ca
2+
 and calmodulin.  
EGTA wells contained 40 µl of 12.5 mM EGTA, 0.375 mM RII phosphopeptide 
substrate, 75 mM Tris (pH 7.5), 150 mM NaCl, 9 mM MgCl2, 0.75 mM DTT, 
0.0375% NP-40, 0.625 µM okadaic acid, 0.125 mM CaCl2, and 5.0 mM ascorbic 
acid. In the calmodulin/Ca
2+
 wells, EGTA was excluded and replaced by 0.313 µM 
calmodulin and 0.75 mM CaCl2. To correct for background absorbance, blanks 
were performed for both the EGTA and calmodulin/Ca
2+
 wells for every sample. In 
these wells, substrate was absent. A phosphate series of 0 to 5 nmol was used for 
calibration, and one aliquot of 50 U (specific activity was determined using Biomol 
assay kit protocol) pure recombinant human CN was used as an interassay control.  
Reactions were initiated via the addition of 15 µl thawed leukocyte lysate sample to 
all wells, resulting in a final assay volume of 55 µl. After 30 min, reactions were 
stopped by adding 100 µl Malachite green reagent, the plate was mixed, and color 
was allowed to develop for 50 min at room temperature before absorbance was 
read at 620 nm using a 96-well plate spectrophotometer (SpectraMax 250, 
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Molecular Devices, Downingtown, PA, USA). The Softmax Pro (version 2.4.1) 
program was used for curve fitting (four-parameter fit).  
For CN activity calculation, background absorbance for EGTA and Ca
2+
/calmodulin 
wells was subtracted and phosphate was quantified with the calibration curve. The 
difference in phosphate between EGTA and Ca
2+







, where WBC is white blood cells [leukocytes]) was defined 
as CN activity. 
 
In vitro CN inhibition 
CsA and TRL were diluted to appropriate concentrations using phosphate-buffered 
saline (154 mM NaCl and 1.4 mM phosphate, pH 7.5). Then 2.5 µl diluted inhibitor 
stock solution was added to 2.5 ml fresh blood to yield final concentrations of 0 to 
5000 µg/L CsA and 0 to 150 µg/L TRL. These samples were incubated for 1 h at 
37°C before leukocyte lysate preparation. 
 
Concentrations of CsA and TRL in peripheral blood  
CsA concentration was measured in whole blood by fluorescence polarization 
immunoassay using an Abbott AxSYM system (Abbott Park, IL, USA). TRL 
concentration was measured in whole blood by microparticle enzyme 
immunoassay using an Abbott IMx system. The assays were performed according 
to the manufacturer’s instructions. 
 
Statistical analysis 
Inhibition curves and IC50 values were fitted and analyzed using sigmoidal dose–
response curves with GraphPad Prism (GraphPad Software, San Diego, CA, USA) 
and are described within the 95% confidence interval (CI) range. Other results are 
reported as mean values, with errors representing 1 standard deviation of the 
mean. In addition, t tests were used to test significance, and statistical significance 





Optimization of assay conditions 
Progress curves were performed to ensure that the initial rate of CN phosphatase 
activity was measured and to enable optimization of assay duration and cell lysate 
concentration. During a 30 min reaction using a lysate of 1.5·10
5
 WBC, activity rate 
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was observed to remain linear and within the range of the phosphate standard 
curve. These conditions were used in all subsequent experiments (not shown). 
 
Maintaining CN activity during storage 
A loss of CN activity was observed repeatedly when leukocyte lysate samples were 
stored at -80°C prior to assay performance. Ascorbic acid subsequently was added 
to our lysis buffer in an attempt to maintain CN in its reduced and active state. 
Samples were lysed and stored in lysis buffer with or without 5.0 mM ascorbic acid 
and then were assayed for CN activity after 0, 1, 2, 7, and 21 days storage at  
-80°C (Figure 2.1).  
                     
Figure 2.1. CN activity after storage of cell lysate at -80°C. Black bars: without ascorbic acid in the 
lysis buffer; gray bars: with ascorbic acid (5.0 mM) in the lysis buffer. Columns represent the means of 
duplicates, and error bars show +1 SD. 
 
The loss of CN activity observed in time was eliminated with the addition of 
ascorbic acid to the lysis buffer. In this way, the CN activity measured in our 
samples could be maintained during storage at -80°C for at least 21 days. 
Subsequent assays always were performed within three weeks of storage.  
When lysate samples were added to the reaction mixture during the CN activity 
assay, the additional ascorbic acid in the lysis buffer was diluted from 5.0 mM to 
1.4 mM. To compensate for this, extra ascorbic acid was added directly to the 
reaction mixture, leading to a 60% increase in the CN activity level. Further 
observations included nearly total inactivation of CN at ascorbic acid 
concentrations above 10.0 mM. Ascorbic acid subsequently was added to a final 
concentration of 5.0 mM in the assay.  
A time-dependent loss of CN activity was also observed when whole donor blood 
was stored at 4°C for a period of 72 h. Aliquots of the stored blood were taken, 
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During the 72-h period, a loss of 47% CN activity was observed despite the 
presence of ascorbic acid in the lysis buffer. Subsequently, all blood was prepared 
as soon as possible after sampling and always within 24 h, when activity loss was 
less than 15%. 
 
Components of the lysis buffer 
In addition to ascorbic acid, various other components of the lysis buffer were 
observed to have a significant effect on CN activity levels. Although many groups 
add the cation chelators EDTA and EGTA to their lysis buffers to inhibit cation-
dependent protease activity, the Ca
2+
-dependent activity of CN is also affected. 
The effect of 0.1 mM EDTA or 0.1 mM EGTA in the lysis buffer on CN activity was 
tested, and it was shown that CN activity was decreased to 21 ± 9 and 52 ± 12%, 
respectively (n = 4), indicating that these cation chelators cause a decrease in 
activity and must be removed.  
The nonionic detergent NP-40 was present in assay buffer and was also observed 
to increase CN activity when added to our lysis buffer. An optimal increase in CN 
activity was observed between concentrations of 0.01 and 0.025% (v/v) NP-40 in 
the lysis buffer. In comparison with the sample lysis without NP-40, increases of 
237 ± 30 and 257 ± 23% in CN activity were achieved by adding 0.01 and 0.025% 
(v/v) NP-40, respectively (n = 2). For subsequent experiments, we chose to add 




A typical phosphate standard curve is shown in Figure 2.2A. Softmax Pro software 
was used for curve fitting. To check linearity of our assay, leukocyte lysate was 
































Figure 2.2. (A) Typical phosphate standard curve. (B) Dilution series of sample. The CN activity is 
calculated with the phosphate standard curve. Diamonds represent sample dilutions, and the dotted line 
indicates the expected dilution line. This experiment was performed in duplicate. 
 
CN assay validation 
To identify the interassay variation, five blood samples of one volunteer taken 
within a 2-month period were prepared separately and analyzed on different days 
(including intraindividual variation). This resulted in a coefficient of variation (CV) of 
10%. One leukocyte lysate sample was also assayed repeatedly within one 
experiment at both high and low concentrations to provide intraassay CVs of 4.5 
and 2.2%, respectively (n = 9). 






, calculated as the mean of the 
activity measured for sample blanks plus 3 standard deviations (n = 9). The lower 
limit of quantification, calculated as the mean of blanks plus 6 standard deviations, 







Analytical recovery was determined by adding recombinant CN to leukocyte 
solution after erythrocyte lysis, resulting in a recovery of 101 ± 13% (n = 3).  
 
In vitro inhibition of CN activity 
The inhibition of CN by CsA and TRL was studied in vitro by adding different 
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volunteers. The inhibition curves are shown in Figure 2.3. IC50 values were 
calculated to be 212 µg/L CsA (95% CI, 67–668 µg/L) and 34 µg/L TRL (95% CI, 
13–88 µg/L). 
            
Figure 2.3. In vitro inhibition of CN by CsA (squares) and TRL (triangles). The means ± 1 SD of 
four healthy volunteers are displayed. Curves were fitted and analyzed using GraphPad Prism. 
 
In vivo inhibition of CN activity 
The in vivo activity and inhibition of CN was also studied using blood samples 
obtained from kidney transplant patients treated with CN inhibitors CsA and TRL. 
The CN activities obtained from patients, both prior to (C0) and 2 h after (C2) oral 
administration of CsA and TRL, are displayed in Figure 2.4.  
 
Figure 2.4. In vivo CN inhibition in patients who received CsA and TRL therapy. Bars represent 
relative CN activity, and diamonds represent full blood drug concentration. (A) C0 and C2 CsA 
concentrations and relative CN activities of four different patients on CsA therapy. (B) C0 and C2 TRL 
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Blood CsA concentration increased from a mean of 94 ± 13 µg/L at C0 to 636 ± 
105 µg/L at C2 and resulted in a 42 ± 8% inhibition of baseline CN activity at C2. 
Blood TRL concentration increased from a mean of 7.1 ± 2.4 µg/L at C0 to 11.5 ± 
4.8 µg/L at C2 and resulted in a 26 ± 5% inhibition of baseline CN activity at C2.  
In addition, t tests were performed to identify differences in drug concentrations 
and CN activities between C0 and C2. For patients treated with CsA as well as 
patients treated with TRL, significantly higher CN activities were observed at C0 
compared than at C2 (Ps = 0.004 and 0.01, respectively), whereas significantly 
lower drug concentrations were observed at C0 than at C2 (Ps = 0.0015 and 0.04, 
respectively). For all patients, higher drug concentrations were observed at C2 than 
at C0, and inhibition of CN was observed at C2.  
To illustrate the potential of this assay for CN monitoring in CNI-treated patients, 
two CN inhibition curves of patients who had undergone kidney transplantation are 
shown in Figure 2.5. In these patients, inverse relations between CN activity and 
drug concentrations are observed. 
 
Figure 2.5. In vivo CN monitoring. Bars represent CN activity, and diamonds represent full blood drug 
concentration. (A) Example of CN inhibition in time by CsA (63-year-old male, 7 days after 
transplantation, 250 mg BID CsA). (B) Example of CN inhibition in time by TRL (47-year-old female, 7 
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The main reason for developing the spectrophotometric CN activity assay was to 
enable assessment of pharmacodynamic CN monitoring in patients treated with the 
CNIs CsA and TRL. The spectrophotometric detection principle allows us to avoid 
the use of radioactive materials and organic solvents. A linear increase of 
phosphate in time was observed for at least 40 min, indicating that substrate is in 
excess, and we decided to use a 30 min running time.  
The concentration of okadaic acid in the final reaction mixture was 0.45 µM, 
inhibiting protein phosphatase 1 (PP1) and PP2A, which have okadaic acid IC50 
values lower than 10 nM. Meanwhile, the IC50 value of CN exceeds 10 mM(19), 
resulting in selective inhibition of these other protein phosphatase enzymes. The 
CN activity was distinguished from okadaic acid-resistant, calcium-independent 
PP2C activity by subtracting the phosphatase activity measured in the presence of 
the calcium chelator EGTA from that measured in excess calcium, resulting in 
calcium-dependent phosphatase activity. PP2C activity is the calcium- independent 
phosphatase activity measured in the presence of okadaic acid and was found to 
be less than 5% of the CN activity in healthy volunteers.  
Optimization studies involved modifications to the lysis buffer. Because these 
resulted in significantly higher activity levels and subsequently in lower detection 
limits, we reduced the requirement for blood and increased lysate storage times. 
To preserve in vivo conditions, and in particular the state of CN inhibition within the 
patient, as much as possible, we chose to maintain samples at 4 °C throughout 
sample preparation. However, the separation of peripheral blood mononuclear cells 
(PBMCs) using a Ficoll–Hypaque gradient, a technique used by many groups, 
should be performed at room temperature to maintain the density of the Ficoll 
solution. Due to this temperature limitation and to the variable amounts of 
erythrocytes, platelets, and granulocytes observed to remain after Ficoll 
separation(10), we decided to simply remove erythrocytes and platelets at 4 °C 
using ammonium chloride lysis buffer and to measure CN activity in total leukocyte 
lysates that contain PBMCs and granulocyte fraction. This technique requires a 
lower volume of blood, and separation is less cumbersome and more reproducible 
than it is with the Ficoll gradient procedure. Support for using material additional to 
PBMCs comes from work by other groups, such as Halloran and coworkers(20), 
who have shown that CN inhibition patterns in whole blood and PBMCs are in 
accord.  
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The observed loss of CN activity on sample storage(10,14) was hypothesized to be 




 center found at 
the CN active site(21,22). This same mechanism was proposed to cause a 10- to 
20-fold loss of activity during the purification of CN from human tissue(21,23). 
Various antioxidants, including ascorbic acid, were found to have an activating 
effect on CN(23). When ascorbic acid was added to our lysis buffer, the level of CN 
activity could be maintained during the storage of lysate samples at -80°C for a 
minimum of 21 days (Figure 2.1). Activity levels were further increased when 
ascorbic acid was added directly to the reaction mixture and an optimal activity was 
achieved in the presence of 5.0 mM ascorbic acid, in agreement with data for 
purified CN published by Sommer and coworkers(23). The effect of the reducing 
agent DTT on enzyme activity and storage was also investigated, but no significant 
effect was observed. 
The cation chelators EDTA and EGTA originally were included in the lysis buffer of 
Fruman and coworkers to inhibit cation-dependent proteases(17). That study 
stated that these subsequently were omitted (in some experiments) because they 
were found to have no protective effect on cellular phosphatase activity. 
Considering that the removal of Ca
2+
 is known to inactivate CN and that EGTA is 
used in this way to define Ca
2+
-dependent phosphatase activity in the assay, it 
does not seem sensible to add cation chelators to the reaction mixture.  
The nonionic detergent NP-40 was added to the lysis buffer at the concentration at 
which we observed maximum CN activity. In one study, NP-40 was used to extract 
CN from the T lymphocyte membrane with which it is reported to be 
associated(24). The release of membrane-associated CN during lysis would 
explain the rise in CN activity observed. However, at NP-40 concentrations higher 
than 0.025% (v/v), the level of CN activity gradually decreases, probably due to 
partial denaturation.  
The phosphate standard curve used for this assay is not linear and becomes 
insensitive at higher phosphate concentrations. Therefore, we recommend that 
samples with an absorbance higher than 0.75 be diluted to ensure assay 
performance. Assay linearity was observed in sample dilution and standard 
addition experiments. In vitro CN inhibition experiments resulted in CsA and TRL 
IC50 values of 212 and 34 µg/L, respectively. These values are similar to those 
described previously(10,11) and agree with reports that TRL is more potent than 
CsA(2).  
CN activity and inhibition was also measured in samples obtained from four kidney 
transplantation patients on CsA therapy and four kidney transplantation patients on 
TRL therapy. In both CsA and TRL patients, CN inhibition is observed given that 
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significantly higher drug concentrations at C2 resulted in significantly lower CN 
activities when compared with C0. Interestingly, no total inhibition of CN activity 
was observed for any patient, a phenomenon that was observed previously by 
others(25). The data presented show that in vivo binding of CNIs to their 
immunophillins and calcineurine is reflected in the CN assay. In vivo measurement 
of CN activity in patients who undergo immunosuppressive therapy by CNIs has 
the potential to guide drug dosing and improve clinical outcome, although the 
benefits of pharmacodynamic monitoring have not yet been proven. The ability of 
this assay for pharmacodynamic monitoring of CN inhibition therapy is illustrated in 
Figure 2.5, where CN activity is measured at multiple time points after drug intake. 
In conclusion, the protocol presented requires 2.5 ml fresh blood and standard 
laboratory equipment. Multiple samples can be prepared and assayed for CN 
phosphatase activity within 1 working day with high intra- and interassay 
reproducibility. The spectrophotometric assay is flexible and can be used to 
measure CN activity in lysates of leukocytes, PBMCs, and combinations of other 
blood cell subsets as well as in other cell types. The assay can be used to monitor 
CN activity in patients that undergo CN inhibition therapy and to assess the role of 
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Background: Calcineurin (CN) activity has the potential to become a 
pharmacodynamic marker to monitor CN inhibitor (CNI) therapy after organ 
transplantation. We investigated the relation between CN activity and cytokine 
secretion at therapeutic cyclosporine (CsA) levels in order to visualize CsA based 
immunosuppression and the applicability of the CN activity marker.  
Methods: Healthy volunteer whole blood incubated with CsA was used as a model 
for allograft recipient blood. CN activity and cytokine (IFNγ, TNFα) secretion after 
CD3/CD28 stimulation were determined. 
Results: A concentration of 25000 µg/L CsA, used as CsA excess, showed only a 
minor increase in CN inhibition and no increase in cytokine (IFNγ, TNFα) inhibition 
when compared to 2500 µg/L CsA. Between therapeutic target concentrations 
(100, 250, 600, and 1700 µg/L CsA) significant differences in inhibition of cytokine 
secretion and CN activity were observed. Inhibition of cytokine secretion ranged 
from 0 to 90% while CN inhibition ranged from 25 to 48%. Additional Cyclophilin A 
could not increase CN inhibition by CsA in cell lysates, while addition of CsA and 
both CsA and Cyclophilin A could.   
Conclusions: Whole blood concentrations of 2500 µg/L CsA approaches 
immunosuppressive saturation and is not yet limited by the CyP content. At the 
therapeutic CsA range, therapeutic target concentrations represented distinct 
immunosuppressive states. In addition, small increases in CN inhibition resulted in 
relative larger suppression of cytokine secretion. Altogether, CN activity as well as 
cytokine secretion after T cell specific stimulation is able to visualize CsA 
pharmacodynamics at relevant in vivo CsA concentrations. 




The calcineurin inhibitors (CNI), cyclosporine (CsA) and tacrolimus (TRL), are still 
widely applied in immunosuppressive regimen to prevent allograft rejection after 
organ transplantation(1). Despite proven efficacy, their apparent lack in selectivity 
remains a major drawback, resulting in an unfavorable cardiovascular profile and 
lack of improvement on the long-term(2). To overcome these issues, CNI 
minimization and avoidance have been investigated with varying success(3-5). 
The wide variation in inter- and intra-individual pharmacokinetic parameters 
requires frequent therapeutic drug monitoring to guide dosing. Further optimization 
of CNI therapy by new monitoring strategies such as the use of pharmacogenetic 
and pharamcodynamic biomarkers are currently under investigation(6,7).   
CNIs suppress allograft reactivity by blocking the intracellular T cell recognition 
signaling pathway(1). In T cells, CsA inhibits calcineurin (CN) phosphatase activity 
that is required for translocation of the transcription factor NFAT into the nucleus. 
Upon translocation, NFAT can transcribe cytokines, such as IL-2, IFNγ and TNFα 
that control T cell mediated immune responses(8). CN inhibition by CsA can only 
occur after dimerization with members of the cyclophilin (CyP) family(9). The 
CsA/CyP complex blocks substrate excess to the catalytic active binding site of CN 
and are therefore the true pharmacological inhibitors of CN(10). Since only partial 
inhibition of CN is observed in transplant recipients and, in vitro, excess of CsA 
only partially inhibited CN activity, it has been suggested that CyPs might limit CN 
inhibition at higher CsA concentrations(11,12). This view was supported by further 
in vitro experiments showing that addition of Cyclophilin A (CyPA), at high CsA 
concentrations, could further increase the degree of CN inhibition(12). The 
relevance of in vitro CyP limitation, for allograft recipients remains unknown.  
To determine the potential of CN activity as a pharmacodynamic biomarker, it is 
relevant to gain insights in the relation between the achieved CNI inhibition at 
therapeutic relevant target levels and the resulting immunosuppressive state, 
measured by cytokine secretion. We therefore investigated the effect of 
representative CsA concentrations in whole blood on CN activity and T cell specific 
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Materials and Methods 
 
Healthy volunteers and kidney transplant recipients blood 
EDTA-or heparin-anticoagulated blood of healthy volunteers was obtained via 
Sanquin Bloodbank (Amsterdam, NL). For simulation of recipient blood, 2 mL of 
EDTA-anticoagulated blood or 1 mL of heparin anticoagulated blood of healthy 
volunteers was incubated (1h, 37°C) with various CsA stock solutions resulting in 
final ethanol concentrations of 0.25% (v/v). For investigation of CsA 
pharmacodynamics, CsA concentrations were used that represented trough and 
peak concentrations regularly found in renal allograft recipients. These conditions 
are referred to as T0 and T2 respectively. As representative CsA concentrations: 
100 µg/L (late T0), 250 µg/L (early T0), 600 µg/L (late T2) and 1700 µg/L (early 
T2), were chosen. 
Six patients on CsA immunosuppressive therapy after living donor renal 
transplantation were included in this study. The patients underwent renal allograft 
implantation within 2 weeks prior to sample date and received a quadruple regimen 
comprising basiliximab (20 mg, days 0 and 4), prednisolone (10 mg/bid), 
mycophenolate mofetil (1 g/bid) and CsA starting 4 mg/kg bid. EDTA-
anticoagulated blood was taken just prior to dose (T0, 12 hours after the previous 
dose) and 2 hours after drug intake (T2). Mean CsA whole blood concentrations at 
T0 was 204 ± 71 µg/L and 983 ± 278 µg/L at T2.  Formal approval from the 
institutional ethics committee was obtained and informed consent for blood 
sampling was obtained from all participants. CsA concentrations of renal allograft 
recipient blood were measured by fluorescence polarization immunoassay using an 
Abbott AxSYM system (Abbott Park, IL, USA). The assays were performed 
according to the manufacturer’s instructions. 
 
Preparation of leukocyte lysate for CN measurement 
Leukocyte lysates of CN inhibitor incubated EDTA-anticoagulated blood were 
prepared as previously described(13). In brief; 2 mL of EDTA-anticoagulated blood 
was lysed with NH4Cl lysis buffer (8.4 g/L NH4Cl, 1.0 g/L KHCO3, pH 7.3) and 
washed twice with 10 mL HBS before resuspention in 1.5 mL Hepes buffered 
saline (HBS, 9.0 g/L NaCl, 10 mmol/L Hepes pH 7.5) for cell count on a Sysmex 
XE2100. 
Cell lyses was performed at a cell concentration of 10·10
6
 cells/mL, therefore 2·10
6
 
cells were resuspended in 200 µL lysis buffer (50 mmol/L Tris HCl pH 7.7, 1.0 
mmol/L dithiothreitol, 5.0 mmol/L ascorbic acid, 0.02% (v/v) NP-40, 50 mg/L 
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soybean trypsin inhibitor, 50 mg/L phenylmethylsulphonyl fluoride, 5.0 mg/L 
leupeptin and 5.0 mg/L aprotinin) and lysed by 3 freeze thaw cycles (liquid N2 / 
30°C). Cell debris was spun down (10 min, 10000g, 4°C) and supernatants were 
snap frozen in liquid N2 before storage at -80°C till cyclophilin A lysate experiments 
and/or CN activity measurement. 
For cyclophilin A (CyPA) / CsA experiment in cell lysate, lysate either or not 
prepared from CsA pre-incubated whole blood or patient blood was incubated with 
CsA and/or CyPA. Final ethanol concentrations were 1%. Samples were incubated 
for 1 hour at 37°C and CN activity was determined directly after incubation.  
 
CN activity measurement 
CN enzyme activity was determined by spectophotometric quantification of 
phosphate released after incubation with the phosphorylated RII substrate as has 
been described before(13). In brief, 15 µL of lysate was added to 40 µL of assay 
buffer (0.313 µmol/L calmodulin, 0.375 mmol/L RII phosphopeptide substrate, 75 
mmol/L Tris pH 7.5, 150 mmol/L NaCl, 9 mmol/L MgCl2, 0.75 mmol/L dithiothreitol, 
0.0375% NP-40, 0.625 µmol/L okadaic acid, 0.75 mmol/L CaCl2 and 5 mmol/L 
ascorbic acid) in presence and absence of substrate. Phosphatase reaction was 
run for 30 min at 30°C, the reaction was stopped by adding 100 µL malachite green 
reagent and the absorbance (620 nm, SpectraMax 250, Molecular Devices, 
Downingtown, PA, USA)) was red after 50 min incubation at RT. Background 
absorbance from blank measurement was subtracted and phosphate was 
quantified out of a 0-1.5 nmol phosphate calibration curve.   
 
IFNγ and TNFα excretion 
For cytokine determination, 30 µL of anti-CD3/anti-CD28 stimulation solution was 
added to the CN inhibitor / Heparin-anticoagulated blood resulting in final 
concentrations of 0.5 mg/L anti-CD28 and 0.12 mg/L anti-CD3. Samples were 
incubated for another 4 hours at 37°C under gentile rotation. After centrifugation 
(1550g, 20 min, 20°C), plasma was collected and stored at -80°C until cytokine 
concentration determination. IFNγ and TNFα plasma concentrations were 
determined using ELISA technique and performed according to manufacturers’ 
protocol, based on(14).  
 
Data analysis 
Data was normalized and expressed as % of blank measurement in order to 
correct for inter-individual variation. Data in the text are presented as mean ± SD. 
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The following materials were used; cyclosporine A, dithiothreitol (DTT), ascorbic 
acid, NP-40, Cyclophilin A (CyPA), and soybean trypsin inhibitor from Sigma 
Aldrich (Steinheim, Germany); phenylmethylsulfonyl fluoride from Merck 
(Darmstadt, Germany), Leupeptin from Roche (Basel, Switzerland); aprotinin from 
Bayer (Leverkusen, Germany); Phosphate standard concentrate from Fluka 
(Buchs, Switzerland); mouse anti-CD28 and mouse anti-CD3 from BD Biosciences 
(San Jose, CA, USA); CN assay components from the Biomol Green Cellular 
Calcineurin Assay Kit Plus from Biomol (Plymouth Meeting, PA, USA). Buffycoats, 




Extent of CsA mediated immunosuppression   
First, the extent of CsA mediated immunosuppression for in vivo conditions was 
investigated. Therefore, the pharmacodynamic effects of high range relevant CsA 
in vivo whole blood concentrations were determined relative to baseline level and a 
condition of CsA excess. Whole blood from healthy volunteers was incubated with 
2500 µg/L and 25000 µg/L CsA. Whole blood incubated with final CsA 
concentrations of 2500 µg/L represented a relevant high range in vivo 
concentration and 25000 µg/L CsA was used as a condition of CsA excess. CN 
enzyme activity and plasma cytokine concentrations after CD3/CD28 stimulation 
were determined, see figure 3.1.  
Compared to 2500 µg/L CsA, a minor but significant decrease in CN inhibition was 
observed for 25000 µg/L CsA (p=0.004). For IFNγ and TNFα no differences in 
plasma cytokine concentrations were observed between 2500 and 25000 µg/L CsA 
with p=0.18 for IFNγ and p=0.25 for TNFα. These results indicated that, in the 
system used, a whole blood CsA concentration of 2500 µg/L approaches the 
maximum immunosuppressive effect of CsA.  
 




















































Figure 3.1. The extent of CsA pharmacodynamics. Healthy volunteer whole blood was incubated 
with final CsA concentrations of 0 (BL), 2500 and 25000 µg/L. A; CN activity (n=14). B; IFNγ (n=6) and 
C; TNFα (n=6).  Data are expressed relative to Baseline (BL) within each volunteer and presented as 
mean + SD. ** for p<0.01 and NS (not significant) for p≥0.05. 
 
Pharmacodynamics under representative in vivo CsA concentrations 
Next, the immunosuppressive dynamics at simulated representative CsA T0 and 
T2 conditions for allograft recipients at early and late stages after graft implantation 





















































Figure 3.2. Pharmacodynamics of CsA for whole blood target conditions.  A; relative CN inhibition 
(n=8) and B; relative TNFα and IFNγ plasma concentrations (n=7). Data are all expressed relative to 
baseline (BL) condition per volunteer and are presented as mean + SD. Statistics presented in the 
figure on the bars represent t-testing with respect to the lower CsA concentration. *** for p<0.001, ** for 
p<0.01, * for p<0.05 and NS (not significant) for p≥0.05 
 
A CN inhibition of 25 ± 8% was observed at 100 µg/L CsA and a CsA concentration 
dependant increase in CN inhibition was found with 48 ± 8% of CN inhibition at 
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1700 µg/L. For IFNγ and TNFα the CsA concentration range was responsible for 
much larger relative dynamic effects between conditions chosen and covered 
almost the full dynamic range from no inhibition to total inhibition of cytokine 
excretion. At 100 µg/L CsA a small (IFNγ, 11 ± 6%, p= 0.004) or no reduction 
(TNFα, p=0.27) was observed, while at 1700 µg/L, cytokine inhibition was 88 ± 
11% for IFNγ and 79 ± 12% for TNFα. Each increase in CsA concentration led to a 
further significant decrease in IFNγ and TNFα.  
 
CyP limitation  
Since the dynamic range of CN inhibition was more narrow than observed for 
inhibition of cytokine secretion, we investigated whether cyclophilin content could 
be responsible for limiting CN inhibition at high CsA concentrations. Limitation of 
CyP on CsA based CN inhibition at a whole blood concentration of 2500 µg/L CsA 
was investigated by (cyclophilin A) CyPA and CsA addition experiments in 
leukocyte lysate. The leukocyte lysate used was obtained from whole blood 
previously incubated with 2500 µg/L CsA (L2500). The lysates were incubated with 
and without additional 5000 µg/L CsA and/or 40000 µg/L CyPA. 
Addition of CsA to L2500 lysate could further increase CN inhibition (p=0.027) and 
an additional increase in CN inhibition was observed by the addition of CyPA and 
CsA (p=0.003). Addition of CyPA itself did not significantly affected CN activity 



























Figure 3.3. Cyclophilin limitation. Sample lysate of full blood incubation with 2500 µg/L CsA. was 
incubated with 40000 µg/L CyPA and 5000 µg/L CsA. BL is leukocyte lysate of whole blood without CsA 
and L2500 is leukocyte lysate prepared from whole blood incubated with 2500 µg/L CsA. Data are 
presented as mean + SD. * is used for 0.05>p>0.01 and ** is used for p≤0.01. 
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Peripheral blood obtained from 6 renal allograft patients treated with CsA was used 
to investigate the relevance of CN inhibition limitation by cyclophilins for allograft 
recipients. Patient samples were taken within the first two weeks after 
transplantation, when whole blood target concentrations or CsA are highest. 
Sample lysate was prepared and lysate prepared from T2 sample was incubated 
with or without 20000 µg/L CsA, 40000 µg/L CyPA or both. After addition of either 
CyPA or CsA to sample lysate, a decrease in CN activity of 8 ± 6% for CyPA 
(p=0.04) and 30% ± 8% for CsA (p=0.004) were observed. Addition of both CsA 
and CyPA led to additional inhibition of CN activity when compared to previous 
conditions.  
 
Relation between CN inhibition and cytokine inhibition 
To investigate the relation between CN inhibition and inhibition of T cell cytokine 
excretion, we plotted the calcineurin inhibition and cytokine excretion inhibition data 
from the previous experiments in one graph, see figure 3.4. 
Here it is shown that at over a certain CN inhibition threshold, which is located 
around 100 µg/L CsA, a small increase in CN inhibition resulted in relative large 
increase in cytokine secretion inhibition. At 2500 µg/L, CsA approaches its maximal 







Figure 3.4. Relation between CN and cytokine inhibition.  Relative TNFα (A) and IFNγ (B) inhibition 
is plotted against the CN inhibition observed at different CsA concentrations. The numbers in the graph 


























































To further optimize CNI therapy, pharmacodynamic monitoring strategies are 
currently investigated as potential tool to guide dosing. Previously we developed a 
CN assay to monitor CN activity in allograft recipients treated with CNIs(13). In the 
present study we assessed the relation between CN activity and the decrease in T 
cell related cytokine secretion at therapeutically relevant CsA whole blood 
concentrations. The results show that at relevant CsA concentrations for renal 
allograft recipients, small changes in CN inhibition resulted in a significant change 
in cytokine secretion and, at high CsA concentrations, approached 
immunosuppressive saturation.  
Complete inhibition of cytokine excretion with only partial inhibition of CN enzyme 
activity has been reported previously(12). These studies have been very valuable 
in understanding the pharmacologic effects of CNIs, but since they have been 
performed in culture systems their clinical relevance and applicability has remained 
unclear. We chose whole blood incubated with CsA as a model to simulate allograft 
recipient blood treated with CsA. Due to the absence of relevant CsA binding sites, 
CsA-related pharmacodynamic parameters under culture conditions may not 
correspond to these markers in whole blood(15). In addition, by using healthy 
volunteer blood, the pharmacodynamic responses could be investigated without 
interference of other concomitantly drugs present and can be expressed relative to 
their baseline level.  
Between the high end of the regular therapeutic range and high excess of CsA, 
only a small increase in CN inhibition was noted, but no differences in cytokine 
secretion, indicating that 2500 µg/L CsA represented the optimal 
immunosuppressive effect in the whole blood system. Using CsA concentrations 
from 100 to 1700 µg/L, covering the range of relevant T0/T2 conditions for renal 
allograft recipients, the decrease in secretion of T cell related cytokine reached 
90% relative to baseline values. In contract, for CN inhibition the relative 
differences were much smaller. In addition, 100 µg/L CsA had only a marginal 
effect on the suppression of cytokine secretion, while already a relative large 
degree of CN inhibition around 25% was found. This could imply that CN inhibition 
has to cross a certain threshold, located CsA concentrations around 100 µg/L or a 
CN inhibition of 25%, before CN inhibition actually results in inhibition of T cell 
cytokines. Thereafter, however, a small additional increase in CN inhibition resulted 
in a relative large increase in suppression of cytokine secretion. The cytokine 
response range was covered by the different representative T0 and T2 conditions 
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chosen and responses to these different concentrations were significantly 
separated. These results indicate that different late and early CsA C0 and C2 
target concentrations represent distinct immunosuppressive conditions. 
It has been demonstrated that cyclophilins can limit CN inhibition by CsA in cell 
culture test systems(12). In addition, partial CN inhibition has been observed in all 
studies that monitored CN activity in allograft recipients(16). These two 
observations led us to investigate the role of cyclophilin as rate limiting step at high 
CsA concentrations. Leukocyte lysate prepared from whole blood incubated with 
2500 µg/L CsA was incubated with and without additional CsA and CyPA. Addition 
of CsA resulted in a further increase in CN inhibition, that was not observed when 
CyPA was added. This confirmed that CyPA did not limit CsA inhibition at clinically 
relevant concentrations. In agreement with previous observations, however, adding 
both CyPA and CsA resulted in significantly less CN activity, confirming that, at 
higher CsA concentrations CyP, may indeed be rate-limiting(12). Therefore our 
results indicate that up to 2500 µg/L CN inhibition by CsA is not limited by lack of 
CyPs. 
To investigate whether cyclophilin limitation is relevant for allograft recipients, we 
repeated these experiments in leukocyte lysate isolated from renal transplant 
recipients treated with CsA-based immunosuppression. Leukocyte lysates were 
obtained just before drug intake and two hours thereafter, representing trough and 
peak levels respectively(17). Addition of CsA to T2 lysates resulted in a further 
decrease in CN activity illustrating that maximum CN inhibition by CsA was not 
achieved under the corresponding whole blood conditions. The number of patients 
used here, are however too small to exclude cyclophilin limitation for CsA therapy 
in allograft recipients.  
Even though these data illustrate the immunosuppressive dynamics of CsA in 
recipients, one important assumption is made, namely that whole blood is a 
relevant and representative matrix to assess the immunosuppressive state. In 
peripheral whole blood there is a large fluctuation in CsA concentrations that may 
not necessarily reflect concentrations at the tissue level.  
In summary, despite redundancy in the immune system, and calcineurin inhibition 
in particular, there was a significant and dose-dependent suppression of cytokine 
synthesis as assessed by secretory capacity. Thus far, pharmacodynamic 
biomarkers have mainly contributed to study drug interactions and visualizing the 
degree of clinical immunosuppression in allograft recipients using culture 
systems(11,18,19). The results of the present study add to our understanding of 
biological variances in CN inhibition and revealed that the degree of clinical 
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Background: In renal transplantation patients, therapeutic drug monitoring of the 
calcineurin (CN) inhibitor cyclosporin A (CsA) is mandatory because of the drug’s 
narrow therapeutic index. Pharmacodynamic monitoring of CN inhibition therapy 
could provide a tool to define and maintain the therapeutic efficacy of CsA therapy. 
We investigated the effect of variation in cell counts of leukocyte subsets on 
leukocyte CN activity measurement in renal transplant recipients. 
Methods: We measured leukocyte CN activity, whole blood CsA concentrations, 
and leukocyte subset cell counts in 25 renal transplant recipients. Blood was 
collected before graft implantation and CsA therapy, 1 day before transplantation 
when CsA therapy was already started, and 5 days after transplantation. Monocyte, 
granulocyte, CD4+ T cell, CD8+ T cell, B-cell, and natural killer cell CN activities 
and CsA inhibition sensitivities were determined in vitro by a spectrophotometric 
CN assay. 
Results: Leukocyte CN activity was inhibited after drug intake. Inter- and 
intrapatient variation in leukocyte subset cell counts resulted in variation of sample 
composition. The mean (SD) CN activity varied among leukocyte cell subsets, 
ranging from 650 (230) to 166 (26) pmol/min./10
6
 cells for monocytes and CD4+ T 
cells, respectively. CsA half maximal inhibitory concentration (IC50) values ranged 
from 15 to 78 µg/L for monocytes and B cells, respectively. 
Conclusion: Inter- and intraindividual leukocyte subset cell count variation can 
affect measured CN activity independent of CsA concentration. Cell-specific activity 
and drug sensitivity should be considered for sample validation to optimize method 








Immunosuppression by calcineurin (CN) inhibition therapy is essential for 
prevention of graft rejection early after renal transplantation. The 2 CN inhibitors 
(CNI) used in transplantation medicine, cyclosporin A (CsA) and tacrolimus, inhibit 
CN after formation of a complex with their corresponding binding proteins, and 
result in suppression of lymphocyte activation(1,2). Unfortunately, side effects, 
such as nephropathy, neuropathy, diabetogenesis, malignancies, and 
cardiovascular disease occur in CNI-treated patients(3–7). Because of the 
unpredictable kinetic profiles of CNIs and potential drug-drug interactions, patients 
receiving CNI therapy require intensive drug monitoring(8). Pharmacokinetic 
monitoring is performed by measuring blood drug concentrations at different time 
points after drug intake(9–11). However, more accurate drug monitoring strategies 
are desired to maximize efficacy of these drugs(12,13). 
Pharmacodynamic monitoring of CNI therapy is a new approach for the 
optimization of CNI monitoring(8), and several methods are available for 
measurement of CN enzyme activity as a pharmacodynamic marker. All methods 
use the same substrate, a 19-amino acid peptide (RII-peptide), which corresponds 
to a part of the regulatory subunit of bovine cAMP dependent protein kinase(14), 
but methods differ in the detection techniques used, such as HPLC-ultraviolet 
measurement of dephosphorylated peptide(15,16), radioactive measurement of 
32
P-labeled phosphate(1,17,18), and absorbance measurement of malachite green 
phosphate reagent(19). In addition, various blood fractions, such as whole blood, 
peripheral blood mononuclear cells (PBMCs), and leukocytes are used as the 
specimen. Although clear relationships between drug concentration and CN activity 
have been observed, no clear relationship between clinical outcome and CN 
activity has been reported(17,20,21). We investigated whether variations in 
leukocyte subset counts would directly affect CN activity measurement 
independent of CNI concentration and potentially confound the use of CN activity 
as a predictive marker. To investigate the effect of sample composition variation on 
CN activity measured in renal transplantation patients, we determined cell-specific 
CN activities and CsA inhibition sensitivities for granulocytes, monocytes, CD4+ T 
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Materials and Methods 
 
Patients and Samples 
Twenty-five patients who underwent living-donor renal transplantation at the Leiden 
University Medical Center were included in this study. Formal approval from the 
institutional ethics committee was obtained, and informed consent for blood 
sampling was obtained from all participants, both patients and healthy volunteers. 
The patient group consisted of 17 male and 8 female recipients with a mean (SD) 
age of 49 (13) years at the time of transplantation. All patients received quadruple 
immunosuppressive therapy with basiliximab, prednisolone, mycophenolate 
mofetil, and CsA (4 mg/kg twice a day), with the latter therapy started 3 days 
before transplantation. EDTA-anticoagulated blood samples from the antecubital 
veins were collected at 3 different time points; 5 days before transplantation (day -
5), when no immunosuppressive therapy had begun; 1 day before transplantation 
(day -1), after initiation of oral CsA therapy but without administration of the other 
immunosuppressive drugs; and 5 days after transplantation (day 5), when full 
immunosuppressive therapy was given. On the day before transplantation (day -1), 
samples were obtained immediately before drug intake (12 hours after previous 
dose), and 2 and 3 hours after drug intake. On day 5 after transplantation samples 
were obtained immediately before and 2, 3, 4, and 6 hours after drug intake. 
 
Blood leukocyte and lymphocyte subset measurement 
Hematologic profiling was performed on a Sysmex XE2100. Lymphocyte subsets 
were analyzed by flow cytometry. The lymphocytes gated in the side-scatter/ CD45 
dot-plot were analyzed for CD3+/CD4+, CD3+/CD8+, CD3+/CD19+ and 
CD3+/CD16/56+ populations using fluorescein isothiocyanate (FITC)- labeled CD4 
(clone SK3), phycoerythrin (PE)-labeled CD8 (clone SK1), APC-labeled CD3 (clone 
SK7) or APC-labeled CD19 (clone SJ25Cl), FITC-labeled CD3, and PE-labeled 
CD16 and PE-labeled CD56 panels on a FACSCalibur (all from BD Biosciences) 
equipped with CellQuest. 
 
Sample preparation for calcineurin activity measurement 
EDTA-anticoagulated blood (2 mL) was treated with erythrocyte lysis buffer (8.4 g/L 
NH4Cl, 1.0 g/L KHCO3, pH 7.3). The leukocytes were then washed twice with 10 
mL Hepes buffered saline (HBS, 9.0 g/L NaCl, 10 mmol/L Hepes pH 7.5) before 
resuspension in 1.5 mL HBS for cell count on the Sysmex XE2100. Leukocyte cell 
lysis was performed for 2·10
6
 cells that were resuspended in 200 µL lysis buffer [50 
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mmol/L Tris-HCl pH 7.7, 1.0 mmol/L dithiothreitol, 5.0 mmol/L ascorbic acid, 0.02% 
(vol/vol) NP-40, 50 mg/L soybean trypsin inhibitor, 50 mg/L phenylmethylsulfonyl 
fluoride, 5.0 mg/L leupeptin, and 5.0 mg/L aprotinin] and lysed by 3 freeze- thaw 
cycles (liquid N2, 30°C). Cell debris was separated by centrifugation (10 min, 
10000g, 4°C), and supernatants were snap-frozen in liquid N2 and stored at -80°C 
before calcineurin activity measurement. 
 
Isolation of leukocyte and lymphocyte subsets for absolute CN activity 
measurement 
Granulocyte and PBMC fractions from healthy volunteers were separated by Ficoll 
density gradient centrifugation. The PBMC fraction was washed with HBS and 





cells/mL. In the granulocyte fraction erythrocytes and thrombocytes were removed 
by erythrocyte lysis with NH4Cl lysis buffer, washed once with HBS, and 
resuspended in HBS. Purity of granulocyte and PBMC fractions was analyzed and 
found to be at least 95% for the PBMC fraction and 90% for the granulocyte 
fraction. Cell fractions were divided into aliquots of 2·10
6
 cells and resuspended in 
165 µL lysis buffer for cell disruption.  
CD3+/CD4+ (CD4+ T cells), CD3+/CD8+ (CD8+ T cells), CD3+/CD19+ (B cells), 
CD3+/ CD16/56+ (NK cells), and monocyte fractions were sorted from the PBMC 
fraction using an ARIA sorter (BD Biosciences). The PBMC fraction was incubated 
for 30 min with FITC-labeled CD4, PE-labeled CD8, and APC-labeled CD3 or APC-
labeled CD19, FITC-labeled CD3, and PE-labeled CD16/56 before cell sorting. 
Isolated fractions were collected in 5-mL BD FACS tubes (BD Biosciences) 
containing 500 µL 50% heat inactivated fetal calf serum in Roswell Park Memorial 
Institute medium. The purity of sorted fractions was analyzed and found to be at 
least 95% for every fraction. Truecount tubes (BD Biosciences) were used for 
controlling cell counts. Sorted cells were spun down (10 min, 500g, 4°C), washed 
once with 250 µL HBS, and resuspended in 165 µL lysis buffer for cell disruption. 
 
Leukocyte and lymphocyte subset isolation for CsA inhibition curves 
Granulocyte and PBMC fractions were isolated from buffycoats (Sanquin) using 
Ficoll density gradient separation. PBMC subsets were isolated using CD4, CD8, B 





 cells/mL in Roswell Park Memorial Institute medium containing 
20% inactivated fetal calf serum and 1% ethanol for 1 hour at 37°C, with final CsA 
concentrations of 0, 0.1, 0.32, 1, 3.2, 10, 32, 100, 320, 1000, 3200, and 10000 
µg/L. Cells were washed once with HBS before cell lysis. 
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Calcineurin activity assay 
Calcineurin activity was determined as previously described(19). In brief, 15 µL of 
lysate was added to 40 µL of assay buffer (0.313 µmol/L calmodulin, 0.375 mmol/L 
RII phosphopeptide substrate, 75 mmol/L Tris pH 7.5, 150 mmol/L NaCl, 9 mmol/L 
MgCl2, 0.75 mmol/L dithiothreitol, 0.0375% NP-40, 0.625 µmol/L okadaic acid, 0.75 
mmol/L CaCl2, and 5 mmol/L ascorbic acid) and to 40 µL of assay buffer without 
substrate to correct for background absorbance. The enzyme reaction was 
performed at 30°C and terminated after 30 min by adding 100 µL of malachite 
green reagent, and then the color was allowed to develop for 50 min at ambient 
temperature. Absorbance was read at 620 nm using a 96-well plate 
spectrophotometer (SpectraMax 250, Molecular Devices), and phosphate was 
quantified using a 0–5 nmol phosphate calibration curve using SoftmaxPro 
(Version 2.4.1) software. 
 
CsA blood concentration 
CsA blood concentrations were quantified using a fluorescence polarization 




Means and SD are used in the text of this manuscript. Data presented in the Figs. 
Are shown as either mean, mean (SE), or box plot. Paired 2-tailed Student t-tests 
were performed to test for statistical significance, which was defined as P < 0.05. 
Inhibition curves and IC50 (half maximal inhibitory concentration) values were fitted 





Leukocyte CN activities and blood CsA concentrations 
The observed leukocyte CN activities and blood CsA concentrations for 25 renal 
transplant recipients, measured at the 3 different time points, are shown in Figure 
4.1.  
CN activities measured in the patients before CsA therapy ranged from 168 to 385 
pmol/min./10
6
 leukocytes. The range of CN activities after oral treatment with CsA 
was 48 to 464 pmol/min./10
6
 leukocytes, and blood CsA concentrations ranged 
from 90 to 2016 µg/L.  
Chapter 4: Calcineurin activity in leukocyte subsets 
 59 
         
 
Figure 4.1. Leukocyte CN activity before and shortly after renal transplantation in patients on 
CsA therapy. Box plots of CsA blood concentration (A) and leukocyte CN activities (B) at 3 different 
time points: day -5, before CsA treatment and graft implantation; day -1, before graft implantation at 
initiation of CsA treatment; and day 5 after transplantation. T0, T2, T3, T4, T5 and T6 represent the time 
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An inverse relationship between CsA drug concentration and CN activity was 
observed on day -1 and day 5. On day -1 and day 5, maximal CN inhibition values 
of 42% and 31%, respectively, were observed 2 hours after drug intake compared 
to T0 CN activities, with mean (SD) T0 CsA concentrations of 195 (86) and 245 
(100) µg/L and T2 concentrations of 1070 (399) and 1037 (312) µg/L, respectively. 
Compared to pretherapy CN activity, a maximum inhibition of 52% and 38% on day 
-1 and 5, respectively, was observed 2 hours after drug intake. CN activity 6 hours 
after drug intake was not significantly different from T0 CN activity on day 5 (P = 
0.12), whereas at 2 hours (P < 0.001), 3 hours (P < 0.001), and 4 hours (P = 0.001) 
after drug intake significantly lower CN activities were found compared to T0. When 
average T0 CN activities were compared to predrug (day -5) CN activities, 15% 
and 13% lower CN activities were observed on day -1 and day 5 respectively, 
though only day -1T0 (P = 0.03) was found to be significantly lower (P = 0.08 for 
day 5 T0). 
 
Peripheral blood leukocyte and lymphocyte subset concentrations 
Leukocyte and lymphocyte subset cell counts were monitored in parallel with CN 
activity. The mean peripheral blood concentrations for leukocyte subsets at all 
sampling points are shown in Figure 4.2A and 4.2B.  
When the leukocyte subset cell counts before graft implantation (day -5 and day -1 
T0) were compared to subset counts after implantation (day 5 T0), an increase of 
total leukocytes (P <0.001), granulocytes (P <0.001), monocytes (P <0.001), and B 
cells (P = 0.009) was observed. On day -1 no significant changes of leukocyte 
subsets were observed, whereas on day 5 a significant decrease in PBMC cell 
counts (starting 4 hours after drug intake, P = 0.012), B cells (starting 3 hours after 
drug intake, P = 0.040), CD4+ T cells (starting 3 hours after drug intake, P = 
0.011), and CD8+ T cells (starting 4 hours after drug intake, P = 0.026) were found. 
All of these changes in peripheral leukocyte subset cell counts affect leukocyte 
sample composition. Figure 4.2C and 4.2D show the relative fractions of leukocyte 
subsets that made up a leukocyte and PBMC sample, which is used as sample in 
other CN activity methods. 
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Figure 4.2. Peripheral blood cell counts of leukocyte subsets in renal transplantation patients 
and the effect on sample composition. Granulocyte and PBMC cell counts in peripheral blood (A) and 
PBMC subset cell counts in peripheral blood (B). Data points represent mean cell counts of all patients, 
and error bars represent SE. (C,D), box plots of subset fractions within leukocyte and PBMC sample, 
respectively. All sampling time points for all patients are included. Sample compositions were calculated 
using full blood differentiates. 
 
CN activities of different leukocyte and lymphocyte subsets 
To investigate whether the changing sample composition within a patient, and the 
variation of sample composition between patients, affects CN activity 
measurement, we determined the cell-specific CN activity for the leukocyte 
subsets. Cell-specific CN activities for 4 healthy volunteers are shown in Figure 
4.3.  
The PBMC fraction seemed to have higher CN activity than the granulocyte 
fraction. The monocytes subset had the highest CN activity in at least 3 healthy 
volunteers. Within the lymphocyte subsets variation in CN was also observed in 
these volunteers. The NK-cell fraction seemed to have the highest CN activity, and 
CD8+ T cells had slightly higher CN activity than CD4+ T cells, which had the 
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Figure 4.3. Cell-specific CN activity. Cell-specific CN activity determined for 4 healthy volunteers and 
expressed per cell. Every bar style represents one individual and columns represent the means of 
duplicates. 
 
CsA inhibition curves for leukocyte subsets 
We determined cell-specific CsA inhibition sensitivities to investigate whether the 
changing sample composition affects the CN inhibition profile of leukocytes. CsA 
inhibition curves obtained for the different leukocyte subsets are shown in Figure 
4.4. Table 4.1 lists CsA IC50 concentrations, which were obtained from the 





Investigation of the usefulness of CN activity measurement as a pharmacodynamic 
marker for CNI therapy requires a clear relationship with therapy outcome. Most 
studies have focused on the relationship between pharmacokinetics and 
pharmacodynamics(22–24), or evaluation of CN inhibition profiles by CsA and 
tacrolimus at different time points after transplantation(25–29). To our knowledge 
only one study, by Fukudo et al., has provided evidence that CN activity is related 
to clinical responses in organ transplantation patients(17), and one other study by 
Sanquer et al. showed that CN activity might be a predictive marker for graft-vs- 
host-disease in allogeneic stem-cell transplantation(30). Both groups used PBMC 
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Figure 4.4. Cell specific inhibition of CN by CsA. CsA inhibition curves for different leukocyte subsets 
fitted with sigmoidal dose–response curves using GraphPad software. CN activity is expressed as 
percentage of CN activity without CsA. Means of duplicates are displayed. 
 
Leukocyte subset IC50 CsA (µg/L) 95% CI (µg/L) 
Granulocytes 21 15 - 31 
Monocytes 15 11 - 21 
CD4+ T cells 36 18 - 71 
CD8+ T cells 25 18 - 36 
NK cells 43 29 - 62 
B cells 78   43 - 142 
 
Table 4.1: CsA IC50 values for different leukocyte subsets. CsA IC50 values and CI were obtained 
from the inhibition curves in Figure 4.4 analyzed by GraphPad software.  
 
We monitored CN activity in the leukocyte fraction because its preparation requires 
less blood and is less cumbersome than PBMC isolation. In a previous study we 
validated our analytical method(19), and as a follow-up we investigated and 
validated our sample choice by monitoring inter- and intrapatient compositional 
variation of the leukocyte fraction and determination of cell-specific activity and 
CsA-inhibition sensitivity.  
Parallel to leukocyte CN activity, peripheral leukocyte subset cell counts were 
monitored in 25 renal transplantation patients (Figure 4.2), and large interpatient 
variation was observed. Significant intrapatient changes were also observed before 
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and after graft implantation, and in time after drug intake when monitored after 
implantation. The granulocytosis, monocytosis, and lymphopenia observed after 
transplantation are caused by surgical trauma and steroid therapy. These changes 
in peripheral blood leukocyte subset concentrations caused time dependent shifts 
in sample composition. To investigate the effect of these changes and 
interindividual variations in leukocyte sample composition on the leukocyte CN 
activity measured, cell-specific CN activities and CsA inhibition sensitivities were 
determined. On average, monocytes have the highest CN activity per cell, as has 
been reported previously(31). Within the lymphocyte fraction, differences in CN 
activity were observed, with the highest CN activity observed in NK cells and the 
lowest CN activity in the T cell subsets for our 4 volunteers. CsA inhibition 
sensitivity profiles for the different leukocyte populations were similar and 
comparable with cell IC50 values reported by Kung et al.(32), a finding that 
indicates that measurement of leukocyte CN inhibition by CsA is not affected by 
variation in sample composition. Taken together, these results show that variation 
in sample composition affects CN activity measured in patient samples, whereas 
CsA inhibition is not affected. Variation in monocyte cell count could have a 
particularly influential effect on CN measurement because monocytes have the 
highest cell-specific CN activity. When linear regression was performed between 
day -5 (pre CsA) CN activities measured in the renal transplantation patients and 
the percentage of cell subsets present in the sample, no clear relationship (max R
2
 
= 0.15, for monocyte fraction) was found, and therefore no effect of sample 
composition on leukocyte CN activity was observed. Variation in monocytes could 
have a greater effect on PBMC CN activities because monocytes account for a 
larger proportion of the PBMC sample, and the inter- and intrapatient variation in 
PBMC fraction composition is much larger than that of the leukocyte fraction (see 
Figure 4.2D). In PBMC samples, monocytes were found to constitute 20% to 80% 
of the sample, and this large variation, based on the larger cell-specific CN activity, 
can significantly influence CN measurement. Halloran et al. compared the PBMC 
fraction with the leukocyte fraction in healthy volunteers and found similar CsA 
inhibition affinities, but larger and more variable inhibition in the PBMC fraction(26). 
When leukocytes are used as sample, the majority of the cells [mean (SD) 75% 
(10%)] are granulocytes, and sample composition changes are relatively small. A 
disadvantage is that a large proportion of the CN activity used for monitoring CNI 
pharmacodynamics is from the granulocyte fraction. Ideally, one would like to 
selectively monitor in the compartment where the drug exerts its effect(21). The 
effector compartment of CsA therapy is thought to be the lymphocyte or, more 
specifically, the T cell populations, and monitoring of these fractions could 
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theoretically enable avoidance of the influence of changing sample composition on 
CN activity. Absolute CN activities would then be more characteristic of 
immunosuppressive status, and observed CN inhibition after drug intake would 
reflect drug pharmacodynamics within the effector compartment and could 
therefore be more relevant. In practice the procedure for routinely sorting and 
preparing these cell fractions for CN activity analyses is very complicated and time 
consuming. In addition, when T cell depletion by anti-thymocyte globulin is used in, 
for instance, treatment of acute rejection episodes, collection of these cells from 
the peripheral blood is very difficult because they are therapeutically removed.  
The CN activities observed in 25 renal transplantation patients were inversely 
related to whole blood CsA concentrations, and for every CN activity time curve 
except that of 1 patient, lower CN activity was observed at T2 than at T0. 
Interestingly, on day 5 we observed significant changes in sample composition by 
time after drug intake that, at least theoretically, could have caused the measured 
decrease in leukocyte CN activity. However, since no changes in leukocyte 
composition are observed within day -1, when a decrease in CN was also 
observed, and as no relationship between leukocyte fraction and CN activity was 
found by linear regression, we conclude that our CN activity measurements reflect 
CN inhibition by CsA. The inhibition of CN by CsA in renal transplantation patients 
is partial and has a temporary duration, as has been observed by other 
groups(25,33). We show that trough CsA concentrations in these patients are 
sufficient to cause CN inhibition.  
The effect of sample composition changes in renal transplantation patients could 
also affect other pharmacodynamic monitoring strategies that are used for 
monitoring CNI therapy, such as cytokine messenger RNA monitoring(34). Also, 
monitoring of other therapies such as inhibition of inosine monophosphate 
dehydrogenase activity by mycophenolic acid in these patients could be affected by 
sample composition variation(35). Investigation of sample composition, cell specific 
activities, and drug sensitivities could therefore be very useful for optimization of 
the clinical sensitivity and specificity of these methodologies. 
In conclusion, we have shown that large inter- and intrapatient variation in 
peripheral blood leukocyte subset cell counts results in a large variation in sample 
composition, which depends on sample choice. In vitro measurement of cell-
specific CN activities indicate that this variation could affect CN activity 
measurement in renal transplantation patients. No relationship was observed 
between sample composition and leukocyte CN activity, and leukocyte CN activity 
can therefore be used for monitoring CN activity in renal transplantation patients. 
Whether measurement of CN inhibition is useful to define and maintain the 
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therapeutic index of CNI therapy is still unknown and requires investigation by 
adequate analytical methods. In this respect further insight in analytical 
confounders is very helpful for optimization of clinical specificity. In future studies, 
larger populations should be monitored for leukocyte CN activity to define the role 
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Background: The calcineurin inhibitors cyclosporin A and tacrolimus are 
immunosuppressive drugs used extensively in allograft recipients. These drugs 
show large inter-individual pharmacokinetic variation and are associated with 
severe adverse affects, including nephrotoxicity and cardiovascular disease. In 
current practice, calcineurin inhibitors are combined with other immunosuppressive 
drugs such as steroids and mycophenolate mofetil. Dosage is titrated based on 
blood concentration measurement. For further optimization of calcineurin inhibition 
therapy, new monitoring strategies are required. Pharmacodynamic monitoring 
strategies constitute novel approaches for optimization of calcineurin inhibitors 
therapy. 
Content: This review focuses on the general aspects of immunosuppressive drug 
pharmacodynamic monitoring and describes the methodologies used for 
monitoring calcineurin inhibition therapy. Two different types of pharmacodynamic 
monitoring strategies can be distinguished: 1) enzymatic strategies, which monitor 
inhibition of drug-target enzyme activity, and 2) immunological strategies, which 
measure cellular responsiveness after in vitro simulated immunological responses. 
Enzymatic tests are drug type specific markers, in which calcineurin activity is 
directly determined. Immunological strategies measure immune responsiveness at 
several levels, such as mRNA transcripts, (intracellular) concentrations/excretion of 
cytokines, expression of surface activation markers, and cell proliferation. This 
review also discusses analytical issues and clinical experience with these 
techniques.  
Summary: The call for new methodologies to evaluate immunosuppressive therapy 
has led to the development of a large variety of pharmacodynamic monitoring 
strategies. The first reports of their clinical relevance are available, but further 
understanding of the analytical and clinical variables involved are required for the 
development of accurate, reproducible, and clinically relevant markers.  




Organ transplantation is a well-accepted treatment for end-stage organ failure of 
various organs including the kidney, heart, lung, pancreas, and liver. For 
successful treatment, adequate suppression of the anti-allograft immunologic 
response is crucial(1). For this purpose, a large assortment of small-molecule 
immunosuppressants is available and used at various stages of the 
immunosuppressive regimen. These drugs include the calcineurin inhibitors 
cyclosporine and tacrolimus, the inosine monophosphate dehydrogenase (IMPDH) 
inhibitor mycophenolic acid, and the mammalian target of rapamycin (mTOR) 
inhibitors sirolimus and everolimus. Each of these agents act by blocking 
intracellular lymphocyte response pathways(1) (figure 5.1).  
 
Figure 5.1. T cell activaton in relation to pharmacodynamic monitoring strategies for calcineurin 
inhibitors.  T cell activation is primed by T cell receptor (TCR) recognition of antigen (Ag) presented by 
MHC molecules on antigen presenting cells (Signal 1). For activation of T cells, co-stimulatory signals 
are required (Signal 2). Thereafter, several transcription factors are activated, including NFAT. Nuclear 
translocation of NFAT is controlled by calcineurin phosphatase, which is inhibited by the calcineurin 
inhibitors CsA and TRL. NFAT is involved in the transcription of several genes to mRNA transcripts 
encoding immune regulatory proteins that are presented on the T cell surface. These products include 
CD40L, Fas, OX40, and the IL-2 receptor α (IL2Rα) and cytokines such as IL-2, IFN-γ, TNFα, and GM-
CSF. The interaction between IL-2 and the high affinity IL2Rα induces T cell proliferation (Signal 3). The 
mTOR inhibitors sirolimus and everolimus inhibit T cell proliferation by inhibition of mTOR downstream 
of the IL2R. Mycophenolic acid (MPA) inhibits T cell proliferation by inhibiting IMPDH dependant 
nucleotide synthesis. Calcineurin activity, mRNA cytokine transcripts, cytokines, expression of surface 
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There is large inter-patient variation in the pharmacokinetic profile of calcineurin 
inhibitors. These agents also produce various adverse effects, such as 
nephrotoxicity and cardiovascular disease(2). In order to control drug over- or 
under-exposure, therapeutic drug monitoring (TDM) is applied. TDM is performed 
via determination of whole blood drug concentrations at various time points after 
drug intake (C0, C2) and estimation of area under the curve (AUC) values(2). 
These TDM strategies have led to significant improvement in immunosuppressive 
treatment by reducing episodes of rejection(2). Unfortunately, over 10% of renal 
transplant recipients experience at least one acute rejection within the first 6 
months post-transplant, and drug toxicity and oversuppression of immune function 
by these drugs seriously hamper long-term success(2,3). A search for new, 
successful immunosuppressive drugs is ongoing. Until new agents are available, 
optimization of current treatments is probably the most effective means to improve 
immunosuppressive treatment(4). Improved monitoring strategies for these drugs, 
including the integration of pharmacogenetics or/and pharmacodynamics within the 
current TDM protocols, could further individualize drug dosing and improve clinical 
performance of these agents(4). Currently, the pharmacogenetic profile of 
calcineurin inhibitors is used as an extension of pharmacokinetics to predict 
individual pharmacokinetic profiles and allow for more rapid and simple 
achievement of therapeutic target drug levels. Pharmacodynamic monitoring 
strategies measure drug effectiveness parallel to pharmacokinetics, and could thus 
provide additional information to define new therapeutic target conditions.         
 
General aspects of pharmacodynamic monitoring strategies for 
calcineurin inhibitors 
 
Why pharmacodynamic monitoring? 
The current TDM approaches are based on concentration measurement, and are 
surrogate markers of drug effect. They are limited in their ability to measure drug 
effectiveness at its immunosuppressive site of action. Pharmacodynamic strategies 
are designed to address this issue. A large amount of evidence supports the 
concept that T cell suppression is the key mechanism by which calcineurin 
inhibitors achieve immune suppression. T cells are therefore interesting candidates 
for pharmacodynamic monitoring strategies(5). Current TDM strategies determine 
blood drug concentrations in extra-cellular or whole blood fractions. However, 
measurement of whole blood or extra-cellular blood concentrations does not 
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necessarily provide an accurate and reproducible reflection of intra-cellular drug 
concentrations within T cells. For instance, calcineurin inhibitors in whole blood are 
highly bound to erythrocytes and lipoproteins. Inter- and intra-patient variations of 
these parameters have been shown to affect calcineurin inhibitor concentrations in 
lymphocytes(6,7). Another variable that could significantly affect distribution of 
immunosuppressive drugs in blood are the drug-efflux transporters. Most 
immunosuppressive drugs are substrates for one or more drug transporter 
proteins, such as P-glycoprotein, that are expressed on T cells(8,9). Intracellular 
drug concentrations can therefore be affected by cellular drug-exporting activity. 
Pharmacokinetic profiles and drug-drug interactions at this level are not monitored 
by current TDM strategies. In order to evaluate and adjust drug dosage based on 
these variables, intracellular T cell drug concentration assays have been 
developed(10).  
Drug concentrations are used as a surrogate marker of effect, but do not 
necessarily correlate with pharmacological response(11). Effect itself is much more 
complex and may involve drug-independent mediators, such as the requirement of 
immunophilins for activity of calcineurin inhibitors and mTOR inhibitors. An 
advantage of pharmacodynamic monitoring strategies is that pharmacological and 
immunological drug-drug interactions can be detected(12).  
 
Enzymatic versus immunological monitoring strategies 
There are two different approaches applied in pharmacodynamic monitoring of 
immunosuppressive drugs: 1) enzymatic monitoring by measurement of the drug 
(main) target enzyme, and 2) immunological monitoring by measurement of ex vivo 
simulated immunological responses. In enzymatic protocols, the intracellular 
enzyme activity of calcineurin is used to monitor CsA and TRL. This enzyme 
system is selectively targeted by one class of drugs and will therefore monitor the 
pharmacodynamics of one immunosuppressive agent (figure 5.2)(13).  
In immunological monitoring protocols, stimulated full blood or isolated cell 
fractions are monitored for T cell activation markers such as cytokine mRNA 
transcripts, cytokine excretion, and surface activation proteins(12). These 
responses are more general measures of immune function. Drug 
pharmacodynamics are determined by quantifying the degree of inhibition of these 
immunological responses that can be ascribed to the immunosuppressive 
agents(s)(14). The calcineurin inhibitors are thought to be the major effectors of 
these parameters, since they are the first in line to interfere with immune 
functioning(1) and the immunological markers used are primarily controlled by 
calcineurin(15). Using these strategies, immunosuppressive synergism, additivity, 
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or antagonism by combinations of various classes of immunosuppressive agents 
can be detected(12). As a consequence, it is more difficult to ascribe the immune 
inhibitory effect to a single component of  combination drug therapy.      
 
 
Figure 5.2. Drug specificity of enzymatic vs. immunological strategies. IL-2 excretion inhibition 
after mitogen stimulation (left) and calcineurin inhibition (right) of CsA, TRL, sirolimus (SRL), and 
everolimus (EVL) in PBMCs isolated from healthy volunteers. Data represent mean of duplicate and are 
expressed as percent of blank measurement. Adapted from(13).  
 
 
Pharmacodynamic monitoring of calcineurin inhibition therapy 
 
Pharmacology of calcineurin inhibitors in T cells 
Calcineurin is the Ca
2+
-and calmodulin-dependent serine-threonine 
phosphatase(16). It consists of a regulatory subunit (CNB) and a catalytic subunit 
(CNA) that becomes available for substrate dephosphorylation after formation of a 
complex between CNB, calmodulin, and Ca
2+
(16). Calcineurin inhibitors inhibit 
calcineurin after binding an intracellular protein (immunophilin). These complexes 
block the active site for large substrates(17). There are two different classes of 
immunophilins: 1) cyclophilins, targeted by CsA, and 2) FK506 binding proteins, 
targeted by TRL(18). 
Calcineurin is involved in a variety of homeostatic processes. Its actions include 
dephosphorylation of multiple phosphoproteins and phosphopeptides, but 
calcineurin is probably best known for its role in T cell activation. T cell receptor 
binding results in increased intracellular Ca
2+
. After binding of calmodulin, this 
intracellular Ca
2+
 activates calcineurin phosphatase activity. Activated calcineurin 
dephosphorylates NFAT (nuclear factor of activated T cells) transcription complex, 
which then translocates to the nucleus(19). Upon co-stimulation, NFAT proteins 
cooperate with members of the activator protein 1 (AP-1) family of transcription 
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factors to transcribe activation-induced genes(20). One of these genes is 
interleukin 2 (IL-2) whose transcription and excretion is controlled by calcineurin. 
IL-2 activates various cells of the immune system including helper T-cells, cytotoxic 
T-cells, NK cells, B cells, and macrophages(21). Other gene products in activated 
mononuclear cells that are under the control of calcineurin are interferon-γ (IFN-γ), 
tumor necrosis factor α (TNF-α), and granulocyte-macrophage-colony stimulating 
factor (GM-CSF)(15,22). IFN-γ is a cytokine predominately produced by activated T 
and NK cell; it exerts its immuno-modulatory effect by induction of MHC 
expression(23). The hematopoietic growth factor GM-CSF is produced by a variety 
of cell types including activated T cells. GM-CSF recruits circulating neutrophils, 
monocytes, and lymphocytes(24). TNF-α is produced by activated T-cells and 
macrophages, activates macrophages and lymphocytes, and enhances their 
cytotoxic potential(25). In addition, transcription of several Th2 cytokines is 
controlled by calcineurin(15). Among these, IL-4 has a broad range of immune 
functions, including stimulation of IgE synthesis in B cells. 
Calcineurin also controls the expression of T cell surface receptors. Their 
appearance is associated with T cell activation, and the receptors constitute 
important immune-response control systems after T cell activation(15). The 
biological effects of IL-2 are mediated via the IL-2 surface receptors, which is 
composed of three subunits; the α-chain (CD25), the β-chain (CD122), and the γ-
chain (CD132)(21). In normal circulating lymphocytes, the IL-2 receptor α is 
expressed in less than 5% of cells at very low levels, but is rapidly transcribed and 
expressed on activated T-cells; this expression is inhibited by CNIs(15,21,26). 
CD40 ligand (CD40L/CD154) is another surface receptor whose expression is 
controlled by calcineurin(15,27). Like TNF-α, CD40L is a member of a large family 
of structurally related ligands that are referred to as the TNF superfamily. These 
proteins regulate functions such as immune responses and haematopoiesis(28). 
CD40L is selectively expressed on activated mature T cells and not on resting T 
cells(29). Its surface expression is controlled by translocation of preformed CD40L 
and mRNA-mediated CD40L expression after anti-CD3 stimulation. This 
expression is observed as early as 1-2 hours after stimulation and peaks at 6 to 8 
hours(29). The effects of TNF ligands are mediated via TNF receptors. Several of 
these ligands are expressed on T cells after activation, and act to control duration 
of T cell responses and T cell survival. One of these ligands is OX40 (CD134), 
which is crucial for T-cell activation and survival(30). OX40 expression is induced 
by T cell receptor stimulation. Expression peaks around 2 to 3 days after 
stimulation and is lost 4 to 5 days after stimulation(31). Another TNF receptor that 
is selectively expressed on activated T cells is Fas (CD95). Interaction of Fas with 
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its ligand (FasL/CD178) triggers rapid apoptosis of activated T cells(32). Other T 
cell receptors that show expression on activated T cells are involved in cell 
adhesive interactions. The leukocyte function associated antigen (LFA-1/CD11a) is 
activated upon TCR stimulation, resulting in increased affinity for its counter-
receptors. This interaction is important for T cell adhesion to endothelial cells, and 
for diapedesis through endothelium. It also acts as a co-stimulatory signal in T cell 
interactions(33). Two other surface activation receptors are CD69 and CD71. 
Activation induced molecule (AIM/CD69) is present on activated but not resting T 
cells, and appears relatively early after T cell activation. CD69 is important in cell 
activation, proliferation, and differentiation(34). The transferrin receptor (TfR/CD71) 
binds iron-loaded transferrin and plays a key role in cell proliferation control, since 
iron is a key nutrient required for cell proliferation. TfR constitutively cycles 
between the endosomal compartment and plasma membrane. Increases in T cell 
surface expression are observed after T cell stimulation(35).   
 
Calcineurin activity measurement 
Calcineurin enzyme activity is determined in excess of all required reagents. 
Therefore in vitro enzyme activity does not necessarily reflect the actual 
intracellular enzyme activity. In this context, this technique may be more correctly 
referred to as a capacity measurement that reflects binding of calcineurin 
inhibitor/immunophilin complexes to calcineurin when fully active(5). Calcineurin 
enzyme activity is regulated intracellularly by Ca
2+
; in naïve T cells, no sustained 
elevation of calcium is present. From an immunological point of view, a lack of 
sustained intracellular hypercalcemia means there is no activation of T cells via 
nuclear factor of activated T-cells (NFAT); thus no suppression of the calcineurin 
pathway is theoretically required. T cells activated by T-cell receptor binding of allo-
antigen have sustained elevation in Ca
2+
 concentrations and calcineurin activity. 
Theoretically, only these cells would require calcineurin inhibition in order to 
suppress the immune response. Adequate binding to and inhibition of calcineurin in 
these cells is therefore crucial for successful immunosuppression. In vitro assays 
approximate these intracellular  conditions. 
In the calcineurin enzyme activity protocols, the Ser-phosphorylated 19-amino acid 
peptide Asp-Leu-Asp-Val-Prol-Ile-Pro-Gly-Arg-Phe-Asp-Phe-Asp-Arg-Arg-Val-Ser-
Val-Cys-Ala-Glu is used as substrate, which corresponds to residues 81-99 of the 
bovine cardiac cAMP-dependent protein kinase regulatory subunit (RII). This 
substrate is not specific for calcineurin, and it can be dephosphorylated by other 
serine-threonine phosphatases (PP)(36). There are four serine-threonine 
phosphatase enzymes (PP1, PP2A, calcineurin, and PP2C). For selective 
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calcineurin activity determination, okadaic acid is used as a specific inhibitor of PP1 
and PP2A. To distinguish calcineurin from PP2C, calcineurin phosphatase activity 
measurement is defined as CsA-inhibitable or Ca
2+
 dependant phosphatase 
activity. In the last case, the Ca
2+





 from the assay. Interestingly, when these two different approaches are 
used in vivo, differences in relative PP2C activity are observed. When CsA is used 
to define calcineurin activity, PP2C phosphatase activity is much larger in the 
calcineurin + PP2C fraction (> 60%(37) of total serine-threonine phosphatase 
activity) than Ca
2+
/calmodulin defined calcineurin activity (< 5%(38,39)). This 
difference can be explained by the mechanism of calcineurin inhibition by CsA. 
CsA itself does not inhibit calcineurin, but requires cyclophilin. Cyclophilins are not 
abundant, and at high CsA concentrations, they limit the ability of CsA to inhibit 
calcineurin(40,41).  
For quantification of the RII substrate dephosphorylation, several detection 
techniques are used. These techniques are based on either determination of the 
radioactive 
32
P isotope, HPLC-UV detection of dephosphorylated peptide, or 
absorbance measurement of phosphate reagent. An overview of the calcineurin 
assay methodologies is shown in table 5.1. 
 
Sample choice and preparation 
Another issue that has been thoroughly investigated and discussed is sample 
choice for calcineurin activity monitoring. The major therapeutic target 
compartment of calcineurin inhibitors is thought to be the T lymphocyte fraction, 
since calcineurin inhibition within these cells is thought to be crucial for their 
immunosuppressive action. Monitoring calcineurin activity in this fraction would 
therefore be most relevant. Unfortunately, no protocol for selective measurement in 
this cell fraction has been developed, though recently an assay for IMPDH activity 
in CD4+ cells has been described(42). Calcineurin activity and inhibition by 
calcineurin inhibitors is monitored in whole blood, leukocyte, peripheral blood 
mononuclear cell (PBMC), and lymphocyte fractions. Two important features of a 
suitable sampling fraction are that the fraction is representative of the 
immunosuppressive site of action and that it is compositionally stable in the sense 
that compositional changes should not affect measurement outcome. Large 
differences in PBMC sample composition are observed for renal transplant 
recipients early after transplantation that can directly confound calcineurin 
measurement based on differences in cell-specific calcineurin activities of 
leukocyte subsets(43).  
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A) Calcineurin activity 
Sample Detection technique Definition of calcineurin activity Refs 
Whole blood Phosphate, by released 
32
P Phosphatase activity in the presence of OA ± CsA 11,37 
Whole blood Phosphate, by released 
32
P Phosphatase activity in the presence of OA ± EGTA 46,66 
Leukocytes Phosphate, Malachite Green Phosphatase activity in the presence of OA ± EGTA 39 
PBMC Phosphate, by released 
32
P Phosphatase activity in the presence of OA ± CsA 11,67 
PBMC Phosphate, by released 
32
P Phosphatase activity in the presence of OA ± EGTA 38,46 
PBMC Dephosphorylated RII, HPLC Phosphatase activity in the presence of OA 51,63 
PBMC Phosphate, by released 
32
P Phosphatase activity in the presence of OA and Mg 52 
Lymphocytes Dephosphorylated RII, HPLC Phosphatase activity in the presence of OA 68 
 
B) Cytokine mRNA 
 
C) Extracellular cytokine concentration 
Sample Stimulation agents Cytokines References 
Supernatant stimulation matrix Anti-CD3/anti-CD28 IL-2 59,70 
Blood supernatant PHA IL-2, IFN-γ 67,71 
 
D) Intracellular cytokine concentration / cytokine producing cells 
Analyte Stimulation agents Cytokines References 
CD4+ and CD8+ T cells PMA/ionomycin IL-2 63 
CD4+ and CD8+ T cells PMA/ionomycin IL-2, IFN-γ, TNFα, IL-4 72 
T cells PMA/ionomycin IL-2, IFN-γ, TNFα, IL-4 14,62,73 
 
E) Surface activation markers 
Analyte Stimulation agents Markers References 
CD4+ T cells Anti-CD3/anti-CD28 CD25, CD69 70 
T cells Concanavalin A CD11a, CD25, CD71, CD95, CD134, CD154 62, 72-74 
 
F) Cell proliferation 
Analyte Stimulation agents Markers References 
Lymphocytes Concanavalin A PCNA 62, 72-74 
 
Table 5.1. Overview of methods used for pharmacodynamic monitoring of calcineurin inhibitor 
therapy. Methods are listed per strategies (A-F) and are subdivided by characteristics. Abbreviations: 
CsA, cyclosporin A; EGTA, ethyleneglycoltetraacetic acid; IFN-γ, interferon-γ; IL-2, interleukin-2; OA, 
okadaic acid; PBMC, peripheral blood mononuclear cells; PCNA, proliferating cell nuclear antigen; PHA, 
phytohemagglutinin; PMA, phorbol 12-mystrate 13 acetate; TNFα, tumor necrosis factor α.  
 
Sample Stimulation agents Cytokines References 
Leukocytes/PBMC PMA/ionomycin IL-2, IFN-γ, GM-CSF 60,69 
Leukocytes/PBMC Anti-CD3/anti-CD28 IL-2, IL-4, TNFα 57,70 
Leukocytes Anti-CD3/anti-CD28 IL-2 59 
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Sample choice can also affect the inhibition profile of calcineurin inhibitors: 
inhibition affinities for CsA were comparable for leukocyte subsets, but erythrocytes 
had significant lower CsA affinity(40).  
Another problem that has been highlighted is the problem of calcineurin activity 
loss due to fractionizing and separation procedures(5) and washing out of drugs 
during cell preparation or by drugs efflux transporters. To overcome some of these 
issues, samples have been treated with inhibitors of drug-efflux transporters or 
have been prepared on ice(10,39).  
 
CN activity in vivo 
Two comprehensive reviews were recently published that report the clinical 
performance of current assays in detail(44,45). Here we briefly discuss the general 
outlines of these studies. When calcineurin activity is monitored in transplantation 
patients treated with either TRL or CsA, a clear inverse relation between drug 
concentration and enzyme activity in whole blood, leukocytes, and PBMC fraction 
is found(39,46,47). A representative example of calcineurin activity and CsA drug 
concentration profiles in a renal transplantation patient the first 6 months after 
transplantation is shown in figure 5.3.   
 
Figure 5.3. Leukocyte calcineurin activity and blood CsA concentration of representative renal 
transplantation patient. Calcineurin activity and CsA blood concentrations were determined at four 
time points. Pre-transplant, before starting CsA therapy; week 2 and week 6 after transplantation when 
reference AUC was 5400 µg/L*h, and 6 after transplantation when reference AUC was 3250 µg/L*h. 
1,2,3,4,5, and 6 represent hours after drug intake, 0 being just before drug intake and 12 hours after 
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The inhibition of calcineurin activity by CsA in these fractions is rapidly reversible, 
and no time lap is observed between CsA drug concentration and calcineurin 
activity(46,48). Interestingly, in the first hours after drug intake, clear inhibition of 
calcineurin activity is observed in patients. After six hours, calcineurin activity 
cannot be distinguished from pre-intake calcineurin activity, while drug 
concentration is still significantly elevated(46,47). Population PK/PD analysis of 
living donor liver transplant recipients showed large inter-individual variability in the 
IC50 value of CsA 200 µg/L (CV = 84%) and TRL 26.4 µg/L (CV = 81%)(38). In 
addition, TRL shows a less dynamic change when compared to CsA in the PBMC 
fraction, and the maximal inhibitory effect of TRL is lower, findings which 
correspond to in vitro data(38).  Another characteristic of calcineurin inhibition by 
either CsA or TRL is that enzyme activity is only partially inhibited in vivo. This 
partial calcineurin inhibition results in greater inhibition of weak stimulatory signals 
compared to maximally stimulatory signals, and is thought to be responsible for the 
presence of immune responsiveness against infections while patients are 
successfully protected from allograft rejection(49). Immunophilin concentrations 
limit calcineurin inhibition by CsA and TRL at high drug concentrations in in vitro 
systems(41). Whether these effects occur under physiological conditions in 
transplant recipients remains unclear, since TRL and CsA concentration 
extrapolations are necessary to translate in vitro results to the in vivo situation. This 
translation is necessary due to abundant irrelevant binding sites in blood that are 
absent in culture medium(50).     
In order to prove that pharmacodynamic monitoring strategies act as a functional 
index of calcineurin inhibitor-based immune suppression, correlation between 
clinical immunological events and measurement is required. Sanquer et al. showed 
that patients with acute grade II or higher graft-versus-host-disease (GVHD) had 
greater calcineurin activity, which could be predicted with a sensitivity of 89% and a 
specificity of 54%(51). However, others have found a decrease in calcineurin 
activity in bone marrow transplanted patients with acute GVHD, suggesting that 
CsA-resistance could be independent of calcineurin inhibition(52).  In liver 
transplantation patients, Fukudo et al. showed that calcineurin activity was 
increased in both TRL and CsA treated patients who suffered from an acute 
rejection(38). In renal transplant recipients, baseline calcineurin enzyme inhibition 
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Immunological monitoring strategies 
Immunological monitoring strategies of calcineurin inhibitor therapy were 
developed early after the introduction of CsA and well before calcineurin was 
identified as its pharmacological target protein(54).  In these assays, third-party 
mixed lymphocyte reactions and IL-2 excretion after mitogen stimulation were used 
as immunologic markers for CsA therapy(54,55). Simulation of an immune 
response, either by mixed lymphocyte reaction, superantigens, or TCR/co-
stimulation directed activation is required for immunological calcineurin inhibitor 
monitoring strategies. Inhibition of immune responsiveness by immunosuppressant 
therapy is often used as readout. This inhibition is measured on different levels, 
including cytokine mRNA, activation surface markers, cytokine producing cells, 
extracellular cytokine concentration, and cell proliferation (see Figure 1 and Table 
1). When patients treated with calcineurin inhibitors are monitored, full blood 
samples or isolated cell fractions are stimulated and incubated for a period of time 
to allow cellular responses and the appearance of markers. Distinct kinetic profiles 
are observed for different markers after stimulation. In addition, the type of stimulus 
employed, affect the kinetic profile of surface markers(56) and cytokine mRNA(57). 
When mRNA gene expression programs were analyzed by microarrays, highly 
similar gene expression patterns were observed for CD3/CD28, 
phytohemagglutinin (PHA), and ionomycin/phorbol-12-myristate-13-acetate (PMA) 
stimulation protocols, illustrating the overlapping usefulness of different types of 
stimulation(58).  
For analyzes of cytokine mRNA, mRNA is isolated from leukocyte or PBMC 
fraction. Quantification of cytokine mRNA is performed by quantitative real-time 
PCR and expressed with respect to housekeeping mRNA (β-actin, cyclophillin B, or 
GAPDH)(57,59,60). Several cytokine mRNA transcripts are used as 
pharmacodynamic markers of calcineurin inhibitor therapy, including IL-2, IFNγ, 
TNFα, IL-4, and GM-CSF. When blood is incubated with a calcineurin inhibitor, a 
significant reduction in these transcripts is found. In addition, when cytokine 
transcripts (IL-2, IFNγ, and GM-CSF) were monitored in renal, cardiac, and liver 
allograft recipients undergoing immunosuppressive therapy, expression was 
decreased and showed an inverse relationship with CsA concentrations. Maximum 
inhibition was observed 2 hours after drug intake corresponding to the peak of CsA 
drug concentration. As observed for calcineurin enzyme inhibition, gene expression 
of NFAT-regulated genes 6 hours after drug intake was comparable to through 
levels(60). In addition, NFAT-regulated gene expression of IL-2, IFN-γ, and GM-
CSF was found to be lower in renal allograft patients on CsA that suffered from 
recurrent infections and malignancies(61).  
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Determination of cytokine producing cells and surface markers is performed using 
flow-cytometry to analyze stained cells. For intracellular cytokine analyzes, 
secretion inhibitors are used during stimulation protocols. Next, permeabilized cells 
are stained and analyzed by flow cytometry and expressed as percent of cytokine 
producing cells(14,62). When monitoring cytokine producing lymphocytes in liver 
allograft recipients, it was found that the percent of IL-2 producing CD8+ T cells 
was higher during acute rejection compared to non rejecting recipients, with a 
positive predictive value of 58% and a negative predictive value of 98%(63). No 
difference was found between percentage of IL-2 producing CD4+ T cells and total 
T cells, suggesting an important role for IL-2 producing CD8+ T cells.     
When cell surface markers are monitored, the expression of T-cells activation 
markers is determined using monoclonal antibodies. Positive cell populations are 
quantified by flow cytometry and expressed as percent of marker positive cells 
within the T cell population(14,62). These strategies have primarily been used to 
study immunosuppressive combination protocols for drug interactions(12). When 
monitored in heart transplanted patients on a CsA-based immunosuppressive 
regime, reductions of the proliferation marker PCNA as well as the T cell surface 
markers CD11a, CD25, CD71, CD95, CD134, CD152, and CD154 were observed 
2 hours after drug intake(64).  
 
Future perspectives 
The current technologies used for pharmacodynamic monitoring of calcineurin 
inhibition therapy have not proved to be clinically useful markers in the 
management of patients on these drugs. More specific samples combined with 
improved understanding and anticipation of analytical variation, particularly 
concerning biological assays, might be important for the development of more 
accurate markers. Most pharmacodynamic monitoring techniques used to date 
have been validated for their analytical performance, but validation methods such 
as sample composition effects on measurement and drug leakage/dilution during 
processing are of key importance. For instance, it is required that the in vivo 
conditions are maintained during the cell isolation/preparation protocol in order to 
measure a representative pharmacodynamic state. It is assumed that 
pharmacodynamic measurement in blood or blood fractions are representative of 
the pharmacodynamic effects at the immunological sites responsible for allograft 
rejection.   
An interesting next step would be to monitor calcineurin capacity or immune 
responses within T cells, which are the specific immunosuppressive target 
compartment of the calcineurin inhibitors(5). This method should avoid analytical 
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variation by sample composition, and absolute values should be more comparable 
between individuals. These immunosuppressive capacities could provide a 
threshold under which no functional T cell activation is possible, even in the 
presence of full T cell receptor binding and maximum intracellular Ca
2+
 influx.  
When such new methods have been developed, clinical validation by means of 
large cohorts is crucial to investigate their efficacy and to determine whether 





The call for more accurate and clinically useful methods for monitoring 
immunosuppressive drugs has led to the development of various 
pharmacodynamic monitoring strategies for calcineurin inhibitors and other 
immunosuppressive agents. The study of pharmacodynamic monitoring of 
immunosuppressive therapy is still in its infancy. Its true efficacy remains to be 
proven, though the first signs of its clinical utility are emerging. Further 
understanding and anticipation of the analytical and clinical variables seem to be 
required for the development of new markers for monitoring calcineurin inhibition 
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To further improve calcineurin (CN) inhibition therapy, pharmacodynamic 
monitoring is currently investigated as a novel approach. Although clear relations 
with pharmacokinetics parameters have been observed, its clinical usefulness has 
not be demonstrated thus far. In order to increase target cell specificity, a T cell 
specific CN activity assay was developed. T-cells were isolated from whole blood 
using anti-CD3 coated paramagnetic beads and the isolated cells were analyzed 
for purity, yield, recovery, cell death and CD4+ and CD8+ subpopulations. T cell 
isolates were 95.5% ± 1.5% pure and no differences were observed for CD4+ and 
CD8+ population distribution before and after isolation, illustrating that 
representative T cell preparations were taken from whole blood samples. The CN 
assay showed linearity and reproducibility and no significant washout of CsA during 
the isolation procedure was noted. CN inhibition was observed when the protocol 
was used to monitor CsA-based immunosuppressive therapy in six stable renal 
allograft recipients.  
The described T cell isolation protocol isolates a representative, highly pure T cell 
sample from whole blood. Adequate analytical performance was observed and the 
method was found to be suitable to monitor T cell specific CN inhibition in stable 
renal allograft recipients receiving CsA.  
 
 




Pharmacodynamic monitoring of immunosuppressive therapy offers new potential 
tools to further improve the therapeutic index of critical dose drugs such as the 
calcineurin (CN) inhibitors cyclosporine (CsA) or tacrolimus. These drugs share a 
large inter-individual variability in pharmacokinetic parameters and are associated 
with considerable adverse effects such as nephrotoxicity, hypertension and 
diabetes mellitus(1). Advanced pharmacokinetics such as intracellular drug 
concentrations, pharmacogenetics and pharmacodynamics are currently 
investigated to increase monitoring specificity and clinical performance of 
calcineurin inhibitors(2-4). 
Several pharmacodynamic monitoring strategies have been described, but only a 
few have been tested in solid organ allograft recipients. Although definite 
correlations between drug concentrations and pharmacodynamics have been 
described(5-7), no clear clinical associations have been reported and further insight 
in analytical variables may lead to identification of more accurate markers(8). We 
have recently reported that matrix composition directly confounds calcineurin 
activity measurement(8). This notion and the generally accepted view that T cells 
are the major target cells of calcineurin inhibitor therapy led us to the development 
of a T cell specific calcineurin activity assay(9).  
 
 
Materials and Methods 
 
Materials 
The following materials were used: cyclosporin A, tacrolimus, dithiothreitol (DTT), 
ascorbic acid, NP-40, and soybean trypsin inhibitor from Sigma-Aldrich, 
phenylmethylsulfonyl from Merck, leupeptin from Roche, aprotinin from Bayer, 
phosphate standard from Fluka, biomol green cellular calcineurin assay kit plus 
from Biomol, fluorescein isothiocyanate (FITC)-labeled CD4 (clone SK3), 
phycoerythrin (PE)-labeled anti-CD8 (clone SK1), APC-labeled anti-CD3 (clone 
SK7), APC-labeled anti-CD2 (clone S5.2), PerCP-labeled anti-CD45 (clone 2D1), 
APC-labeled anti-CD19 (clone SJ25Cl), FITC-labeled anti-CD3, PE-labeled anti-
CD16 and anti-CD56 and anti-CD3 coated paramagnetic beads, all from BD 
Biosciences and RPMI 1640, iFCS, penicillin/streptomycin and paramagnetic anti-
CD3-beads from Invitrogen.   
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Patients and healthy volunteers 
EDTA-anticoagulated blood from the anticubal veins of healthy volunteers and 
renal allograft recipients receiving a CsA based immunosuppressive regimen was 
used for validation of the T cell calcineurin activity assay. Formal approval from the 
institutional ethics committee was obtained, and informed consent for blood 
sampling was obtained from all participants. The renal allograft recipient group 
underwent graft implantation 12 to 24 months prior to sample date and received 
dual immunosuppressive therapy including prednisolone (10 mg daily) and CsA. 
CsA dosage was controlled by estimated min-AUC(0,2,3 h) aiming at a target 
AUC(0-12 h) of 3250 µg/L*h(10). 
 
T cell isolation, sample preparation and calcineurin assay 
EDTA-anticoagulated blood (1.5 mL) was incubated with 60 µL of pre-washed (0.1 
% BSA, 10 mM Hepes, 9.0 g/L NaCl, pH 7.5) anti-CD3 paramagnetic bead 
suspension for 25 minutes at 4°C with continuous tilting and rotation. After 
incubation, samples were placed in a magnet (DynaMac-2, Invitrogen) for 1 min. 
and supernatant was discarded. T cells were washed 4 times with 1 mL erythrocyte 
lysis buffer (8.4 g/L NH4Cl, 1.0 g/L KHCO3, pH 7.3). During this washing procedure 
samples and washing solution were kept on ice. Isolated and washed T cells were 
directly lysed by addition of 100 µL lysis buffer (50 mM Tris-HCl (pH 7.4), 1.0 mM 
DTT, 5.0 mM ascorbic acid, 0.02% (v/v) NP-40, 50 mg/L soybean trypsin inhibitor, 
50 mg/L phenylmethylsulfonyl fluoride, 5.0 mg/L leupeptin and 5.0 mg/L aprotinin) 
and three freeze-thaw cycles (liquid N2 / 30°C). Cell debris and beads were spun 
down (10.000g, 10 min, 4°C), supernatant was collected and snap frozen in liquid 
N2 before storage at -80°C until CN activity measurement. 
The calcineurin activity assay used, was previously described, with one 
adjustment; a 0-1.5 nmol phosphate calibration curve was used for phosphate 
quantification(11). Calcineurin activity was expressed as nmol phosphate released 
per minute per µg protein. Protein concentrations of lysates were determined using 
the Coomassie Plus protein assay (Thermo Scientific, Rockford, IL, USA).  
 
Cellular analysis 
T-cell recovery, purity and yield were calculated from hematological analyses 
before and after T-cell isolation. T-cell concentrations of the starting material 
(whole blood) were calculated from leukocyte differentiates, performed on a 
Sysmex XE2100, and lymphocyte T-cell differentiations obtained using flow-
cytometry. Lymphocytes gated in the side-scatter / CD45 dot-plot, were analyzed 
for CD3+, CD3+ /CD4+ and CD3+/CD8+ populations.   
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For analyzes of the isolated T-cell population, the paramagnetic beads were 
detached by resuspention in RPMI culture medium containing 10 % inactivated 
fetal calf serum, 100 U/mL penicillin and 100 µg/mL streptomycin and overnight 
incubation in a humidified environment (5%, CO2). Next day, the soaked off beads 
were removed by use of magnet. From the supernatant, manual erythrocyte and 
leukocyte counts were performed. Cell death was determined by trypan blue 
staining and leukocyte differentiate were determined after May-Grunwald/Giemsa 
staining of cytospins (Sysmex XE2100).  
Determination of the T-cell purity within the lymphocyte population was performed 
by flow-cytometric analysis of B-, NK- and T-cells. Since the CD3 epitope was 
absent after detachment of T cells from the CD3-coated paramagnetic beads, we 
used the CD2 epitope as T cell marker for the isolated lymphocytes. Here, 
lymphocytes gated in the side-scatter / CD45 dot-plot were analyzed for CD19+, 
CD16/56+ populations in one panel and CD2+, CD2+/CD4+ and CD2+/CD8+ 
populations in a second panel.    
 
Data analysis 
Data are presented as mean ± SD. One-way ANOVA was used for statistical 
analysis of the multiple groups in the storage experiments. Statistical difference 
between two groups was determined by student t-test and statistical difference was 




The final T cell purity isolated from healthy volunteer blood (n=15) was 95.5% ± 
1.5% with 4 ± 1.2% of erythrocytes present (table 6.1).  
 
      Lymphocytes subsets 
erythrocytes (%) granulocytes (%) monocytes (%) CD19+ (%)  CD15/56+ (%) CD2+ (%) 
4.0 (1.2) n.d n.d 0.09 (0.06) 0.3 (0.2) 95.5 (1.5) 
 
Table 6.1. T cell sample composition. Purity of T cell isolate was determined for 15 healthy 
volunteers. Data are presented as mean % (SD) of contaminants present in isolate. n.d.; non detected. 
 
A yield of 0.86 ± 0.44 ·10
6
 T cells and a recovery of 42% ± 14 % was found. Since 
the recovery was relatively low the CD3 coated beads were up-titrated, but did not 
increase T cell recovery. Significant cell death after isolation was excluded by 
trypan blue staining, being only 7% ± 2%. No changes were observed in CD4+ and 
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CD8+ T cell subpopulations before and after the isolation procedure (p=0.89 and 
0.84 respectively, n=5). 
Blood was stored at 4°C for 0, 4, 8 and 24 hours (n=3) after collection and no 
decrease in activity was detected (p=0.78). Stability of calcineurin activity during 
lysate storage was investigated for 0,1,2,6 and 15 days and a decrease in 
calcineurin activity was observed after 2 days (13%, p=0.046). Subsequently, 
sample lysates were stored for maximal 1 day before calcineurin activity 
measurement.    
Linearity was observed when T cell-beads fractions isolated from healthy 
volunteers were serial diluted with beads without T cells, before T cell lysis (figure 
6.1).  
 
     
 
Figure 6.1. Linearity of calcineurin assay. Upper; a typical calibration curve of the calcineurin assay. 
Lower; linearity of calcineurin assay determined by dilution of T-cells. These results are presented as 
mean ± SD (n=3) and calculated from calibration curve shown in upper figure.  
 
The detection limit of the phosphate measurement was 0.15 nmol phosphate when 
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When blood from one healthy volunteer was taken 4 times over a 4 month period, a 
reproducibility including intra-individual variation of 7% was found.  
To investigate whether CsA is washed out during the isolation procedure, we 
incubated whole blood with CsA and tested whether doubling of the washing steps, 
required for T cell isolation, decreased calcineurin inhibition by CsA. We could 
detect a calcineurin inhibition of about 30% for final whole blood CsA 
concentrations of 1000 and 2500 µg/L (p=0.0011) and no loss of calcineurin activity 
(p=0.18) or washing out of CsA (p=0.57) during the isolation procedure (figure 6.2).  
 
Figure 6.2. Washing out of CsA. Washing out of CsA from the T cells during the isolation procedure 
was investigated by doubling of the isolation washing steps for 2 whole blood CsA concentrations. The 
results are presented as mean ± SD (n=7 for BL; n=4 for 1000 µg/L CsA; n=3 for 2500 µg/L). BL 
(Blank); without CsA 
 
To test whether the T cell calcineurin activity protocol can be used for monitoring 
CsA therapy, we monitored T cell calcineurin activity in 6 renal allograft recipients 
that received CsA therapy. The observed T cell calcineurin activities and whole 
blood CsA concentrations of two representative patients are illustrated in figure 6.3.  
Significant inhibition of T cell calcineurin activity was observed (14%) when 
activities just before drug intake (T0) (23.3±9.6 pmol phosphate/min./µg protein) 
were compared to activities 2 hours after drug intake (T2) values (20.0±7.8 pmol 
phosphate/min./µg protein, p=0.026) with corresponding CsA concentrations of 






BL 1000 µg/L CsA 2500 µg/L CsA







































Figure 6.3. T cell calcineurin inhibition and whole blood CsA concentrations in two 
representative allograft recipients. T cell calcineurin activity was monitored parallel to whole blood 
CsA concentration. T0, sample taken at time point just before drug intake (12 hours after previous dose) 





One of the major issues associated with the current pharmacodynamic monitoring 
strategies for calcineurin inhibition therapy is the large inter-individual variability 
observed that does not necessarily correlates to clinical endpoints. Part of this 
variation may be ascribed to either sample choice, sample composition and/or 
accuracy of the analytical techniques used(8,9). A T cell specific protocol for 
measurement of calcineurin activity might overcome most of these issues. Final T 
cell isolates were of high purity, ensuring that calcineurin activity measured after 
isolation was not significantly confounded by the presence of other cells. For 
instance, erythrocytes have only low cellular calcineurin activity(12), but they do 
contain proteins and when calcineurin activity is expressed per protein, large 
variations in erythrocytes could seriously confound measurement outcome. In 
addition, no changes in the CD4+ and CD8+ population distribution were observed 
within the T cell fraction after isolation. This indicated that a representative T cell 
sample was taken from the blood. 
Recovery of T cells was relatively low, but up-titration of the beads did not increase 
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volunteers as well as for renal allograft recipients was however sufficient to perform 
the calcineurin assay with a suitable analytical reproducibility. The most likely 
cause of the low recovery is cell loss during the bead/T cell washing procedure. 
This is confirmed by lower calcineurin measurement and lower protein 
concentration measurement after doubling of the washing steps. 
Storage of T cell lysate showed a decrease in calcineurin activity starting already at 
the 2nd day after initial storage. Previously is was observed that storage of 
leukocyte lysate using the same lysis buffer could be stored up to 3 weeks(11). The 
most likely explanation for this discrepancy is the presence of the paramagnetic 
beads or remainings thereof in the cell lysate. Its possible that remainings of the 
beads could for instance oxidize and subsequently inactivate calcineurin(13,14). 
Loss of intracellular CsA during T cell isolation was found to be of only limited 
relevance, since doubling of the washing steps did not affect calcineurin inhibition 
by CsA. This indicates that the cellular conditions are maintained throughout the T 
cell isolation procedure.  
In this protocol we couple the T cell isolation protocol to a calcineurin assay for 
pharmacodynamic monitoring of CsA therapy. The isolation protocol could however 
also be followed by other enzymatic assays such as mTOR activity, inosine 
monophosphate dehydrogenase (IMPDH) or cellular drug concentration 
measurement that could be of interest for allograft recipients. Intracellular T cell 
analysis could also be of interest in other diagnostic fields; a wide range of other 
intracellular enzymes and markers can be analyzed in T cells isolated from 1.5 mL 
of blood. 
In conclusion we present a validated protocol for the isolation of highly pure T cell 
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The calcineurin inhibitors cyclosporin A and tacrolimus and the inhibitors of the 
mTOR, sirolimus and everolimus bind immunophilins that are required for their 
immunosuppressive action. In contrast to cyclosporin A, tacrolimus and the mTOR 
inhibitors (MTIs) share common immunophilins, the FK506-binding proteins 
(FKBPs). We investigated the immunosuppressive interactions of MTIs on 
tacrolimus based immune suppression, since insights in immunological drug–drug 
interactions can be very relevant for optimization of immunosuppressive regimens 
in allograft transplantation medicine. 
Isolated peripheral blood mononuclear cells from healthy volunteers were 
incubated with combinations of MTIs and calcineurin inhibitors and when monitored 
for calcineurin activity and IL-2 excretion after mitogen stimulation, tacrolimus IC50 
concentrations shifted to higher concentrations in the presence of MTIs. This 
antagonism was absent for cyclosporine A, reproducible for 10 healthy volunteers 
(p < 0.001) and stronger for sirolimus than for everolimus. When cell lysate was 
treated with and without MTI, tacrolimus and FKBP12, FKBP12 could increase 
calcineurin inhibition by tacrolimus and reverse the MTI antagonism for both MTIs. 
These results demonstrate that FKBP12 can be rate limiting for calcineurin 
inhibition at high tacrolimus concentrations and that the antagonism of sirolimus 
and everolimus on tacrolimus based immune suppression is mediated via 
saturation of FKBP12. 
 
 




After organ transplantation, immune suppression to prevent allograft rejectionis 
crucial for successful graft survival. Several immunosuppressive agents, such as 
the calcineurin (CN) inhibitors tacrolimus (TRL) or cyclosporin A (CsA) and the 
mammalian target of rapamycin (mTOR) inhibitors sirolimus (SRL) or its derivative 
everolimus (EVL), are used and combinational therapies are applied to achieve 
optimal immunosuppressive effect and reduce individual drug toxicity(1). CsA and 
TRL inhibit CN, a calcium/calmodulin dependent serine/ threonine protein 
phosphatase that plays an important role in mediating T-cell receptor stimuli into 
cytokine (IL-2, IFNγ) transcription. SRL and EVL inhibit mTOR, a kinase with a key 
function in cell cycle progression(1,2). Both classes of drugs inhibit enzyme activity 
only after binding to specific intracellular binding proteins, so called 
immunophilins(3,4). CsA binds selectively to the cyclophilin class of immunophilins 
that are cytosolic peptidyl–prolyl isomerases, while TRL and the mTOR inhibitors 
(MTIs) bind to the FK506-binding proteins (FKBP) that also exert peptidyl–prolyl 
isomerase activity(3). SRL, EVL and TRL bind similar FKBPs(5,6), while distinct 
and selective inhibition of respectively mTOR and CN is observed (7). Since similar 
FKBPs are required for successful CN inhibition by TRL and mTOR inhibition by 
SRL or EVL, pharmacological drug–drug interactions have been investigated by 
several groups. Dumont et al. has shown that SRL and TRL are reciprocal 
antagonists(5,8), while others have demonstrated immunosuppressive synergism 
of these drugs(9,10).  
In clinical practice, pharmacokinetic drug–drug interactions on metabolic and drug-
transporter proteins are therapeutically avoided or adjusted for by therapeutic drug 
monitoring. When drug–drug interactions occur on the pharmacologic level and 
thus inhibit each others effectiveness, concentration measurement becomes less 
relevant since it is unable to detect this interaction(10). In addition, combinations of 
immunosuppressive drugs might be associated with immunosuppressive 
synergism(11). Pharmacodynamic monitoring strategies that can detect these 
interactions may prove to be useful to further optimize immunosuppressive 
regimen(12). In this respect we studied the interaction of EVL and SRL on TRL 
based immunosuppression in peripheral blood mononuclear cells (PBMCs) isolated 
from healthy individuals. Pharmacological interaction was investigated by 
measurement of CN enzyme activity. For immunological monitoring, the IL-2 
downstream product of CN was used. 
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Materials and methods 
 
Materials 
The following materials and reagents were used: Buffy coat were purchased from 
Sanquin (Amsterdam, NL). RPMI 1640, heat inactivated fetal calf serum (iFCS), 
penicillin/streptomycin, phytohemagglutinin (PHA) and IL-2 EASIA kit from 
Invitrogen (Carlsbad, CA), NP-40, soybean trypsin inhibitor, cyclosporin A, 
tacrolimus, sirolimus (rapamycin), FKBP12 and phorbol-12-myristate-13-acetate 
(PMA) from Sigma–Aldrich (Steinheim, Germany). Phenylmethylsulfonyl fluoride 
from MERCK (Darmstadt, Germany), leupeptin from Roche (Basel, Switzerland), 
aprotinin from Bayer (Leverkusen, Germany), phosphate standard concentrate and 
everolimus from Fluka (Buchs, Switzerland) and the malachite green calcineurin 
activity assay kit from Biomol (Plymouth Meeting, PA). All other chemicals and 
reagents were of the highest available grade. 
 
Immunosuppressants 
The immunosuppressants CsA (MW 1203), TRL (MW 804), EVL (MW 958) and 
SRL (MW 914) were dissolved in ethanol and serial diluted in ethanol. These 
immunosuppressant stock solutions were diluted in the experiments resulting in 
final CsA, EVL and SRL concentrations of 0.025, 0.25, 2.5, 25, 250 and 2500 µg/L 
and final TRL concentrations of 0.00625, 0.0625, 0.625, 6.25, 62.5 and 625 µg/L. 
Final ethanol concentrations were 0.25% for single immunosuppressant 
experiments and 0.5% for the interaction experiments. For the CsA inhibition curve 
in Figure 7.2, CsA ranged from 0.1 to 3600 mg/L with final ethanol concentrations 
of 1%. The ethanol concentrations resulted in a 5% increase in CN activity when 
compared to an ethanol blank (n = 4, P = 0.04).  
 
PBMC isolation and cell culture  
Peripheral blood mononuclear cell (PBMC) fraction of healthy volunteer blood was 
isolated from buffy coats by ficoll density gradient centrifugation. Remaining of 
erythrocytes and thrombocytes were lysed and washed out by NH4Cl lysis buffer 
(8.4 g/L NH4Cl, 1.0 g/L KHCO3, pH 7.3) and resuspended in phosphate buffered 
saline (PBS, 154 mmol/L NaCl, 1.4 mmol/L phosphate pH 7.5) for cell count on a 
Sysmex XE2100. Cells were centrifuged (10 min., 350g, 4 °C) and resuspended at 
a concentration of 2·10
6
 cells/mL in RPMI 1640 cell culture containing 10% iFCS, 
100 U/mL penicillin and 100 µg/mL streptomycin.  
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For CN activity measurement, cells were incubated for 1 h at 37°C with 
immunosuppressant(s). After incubation, samples were centrifuged (10 min, 350g, 
4°C) and cell pellets were washed once with 400 µL HEPES buffered saline (9.0 
g/L NaCl, 10 mmol/L Hepes pH 7.5), resuspended in 400 µL lysis buffer (50 
mmol/L Tris–HCl pH 7.7, 1.0 mmol/L dithiothreitol, 5.0 mmol/L ascorbic acid, 0.02% 
(v/v) NP-40, 50 mg/L soybean trypsin inhibitor, 50 mg/L phenylmethylsulphonyl 
fluoride, 5.0 mg/L leupeptin and 5.0 mg/L aprotinin) and lysed by 3 freeze thaw 
cycles (liquid N2 /30°C). Cell debris was centrifuged (10 min, 10000g, 4°C) and 
supernatants were snap frozen in liquid N2 before storage at -80°C till CN activity 
measurement(13). 
For IL-2 excretion measurement, cells were stimulated by PHA/PMA 1 h after 
incubation with immunosuppressant(s), and incubated overnight at 37°C in a 
humidified environment (5%, CO2). PMA stock solution was 4000 times diluted in 
cell cultures resulting in a final PMA and DMSO concentration of respectively 5.3 
nM and 0.025%, and PHA was 100 times diluted according to manufacturers’ 
protocol. The next day, cells were centrifuged (10 min, 350g, 4°C) and supernatant 
was stored at -20°C until IL-2 concentration measurement. 
 
Cell lysate experiments 
In order to investigate the role of FKBPs, we isolated PBMCs from buffy coats 
obtained from healthy volunteers. Untreated PBMCs were lysed as described 
before and aliquoted lysate was incubated in duplicate (1 h, 37°C) with and without 
TRL, MTI and FKBP12 resulting in final lysate concentrations of 25 µg/L TRL, 50 
µg/L of SRL/EVL and 2000 µg/L and 10000 µg/L of extra FKBP12. At these 
concentrations the molar concentrations of the MTIs, TRL and FKBP12 were of the 
same order of magnitude. Directly after incubation CN activity was determined. 
 
Calcineurin assay 
Calcineurin phosphatase activity was measured as described before(13). In brief, 
CN phosphatase was quantified by measurement of the dephosphorylation of the 
phosphorylated RII substrate in the presence of okadaic acid. 15 µL of sample lysis 
was added to 40 µL of assay buffer (0.313 mmol/L calmodulin, 0.375 mmol/L RII 
phosphopeptide substrate, 75 mmol/L Tris pH 7.5, 150 mmol/L NaCl, 9 mmol/L 
MgCl2, 0.75 mmol/L dithiothreitol, 0.0375% NP-40, 0.625 µmol/L okadaic acid, 0.75 
mmol/L CaCl2 and 5 mmol/L ascorbic acid) and substrate blanks were used to 
correct for background absorbance. The assay was run for 30 min. at 30 °C and 
stopped by addition of 100 µL of malachite green reagent. Colour was developed 
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the next 50 min. before absorbance measurement at 620 nm, and phosphate was 
quantified by means of a 0–5 nmol calibration curve. 
 
Cytokine concentration measurement 
IL-2 concentrations were determined with the EASIA kit (Invitrogen) and performed 
according to manufacturers’ protocol. 
 
Data analysis and statistics 
Values are presented as mean of duplicate and blank experiments were performed 
in quadruple. CN activity and IL-2 concentrations were expressed as % of blank 
measurement in order to remove inter-individual variation in absolute CN activity 
and IL-2 excretion. CN inhibition curves and IL-2 cytokine inhibition curves were 
fitted by sigmoidal dose– response curves using GraphPad software and IC50 
concentrations, Emax values and 95% confidence intervals (CI) were obtained 
from these regression analysis. Student t-tests were used to test significance and 





IL-2 inhibition by TRL and CsA in the presence of EVL and SRL  
To gain insights whether and under which conditions the immunological interaction 
between the MTIs and TRL occurred, we firs measured the effect of the MTIs on 
IL-2 inhibition by TRL. PBMCs isolated from healthy volunteers were stimulated 
using PHA/PMA and IL-2 excretion was measured in the presence of TRL or CsA 
and various concentrations of EVL or SRL. The results of these experiments are 
shown in figure 7.1 and the obtained IC50 values of CsA and TRL in the presence 
of various concentrations of EVL and SRL are listed in table 7.1.  
The MTIs inhibited IL-2 excretion in the PHA/PMA stimulated PBMCs themselves 
at the concentration range used and this inhibition increased with increasing 
concentrations of MTI, though no clear sigmoidal concentration response 
relationship was visible as well as no inhibition of total IL-2 excretion. When high 
TRL concentrations were used in combination with EVL or SRL, low concentration 
of the MTIs did not significantly effect IL-2 inhibition by TRL.  
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Figure 7.1. IL-2 inhibition by TRL and CsA in the presence of MTIs. IL-2 inhibition by TRL was 
determined in the presence of various concentrations of SRL (A) and EVL (B). (C) and (D) show the CN 
inhibition by CsA in the presence of the same concentrations of SRL and EVL respectively. Data show 
the mean of duplicate measurement for one healthy individual. 
 
  [mTOR inhibitor] Tacrolimus Cyclosporin A 
  in µg/L IC50 in µg/L (95% CI) IC50 in µg/L (95% CI) 
Sirolimus 0 0.20 (0.12 – 0.33) 8.5 (2.6 - 27) 
 0.25 0.14 (0.09 – 0.23) 2.7 (1.1 - 6.7) 
 2.5 0.22 (0.11 – 0.44) 2.1 (1.1 - 4.1) 
 25 1.6 (0.57 - 4.6) 4.7 (2.4 - 9.2) 
 250 11 (4.8 - 26) 1.2 (0.35 - 4.1) 
 2500 114 ( 56 – 234) 0.59 (0.05 - 6.8) 
Everolimus 0 0.15 (0.06 – 0.36) 9.5 (4.7 - 19) 
 0.25 0.13 (0.05 – 0.31) 3.6 (2.1 - 6.3) 
 2.5 0.13 (0.05 – 0.38) 4.7 (2.9 - 7.5) 
 25 0.28 (0.14 – 0.55) 2.1 (0.84 - 5.0) 
 250 2.6 (1.4 - 4.6) 5.6 (3.1 - 10) 
  2500 19 (11 - 32) 2.0 (0.84 - 4.9) 
 
Table 7.1. IL-2 IC50 values of TRL and CsA in the presence of various concentrations of SRL and 
EVL. IC50 values and 95% confidence intervals (CI) were obtained from the sigmoidal concentration–
response regressions when the data in Figure 7.1 are presented with the CNI inhibitor on the x-axis and 
the individual curves are variations in EVL or SRL concentrations. 
 
However at higher concentrations (250 µg/L), significant shifts in IL-2 IC50 values 
were observed. MTI concentrations of 25 µg/L and higher reversed IL-2 inhibition 
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the TRL concentration and seems to be less for EVL when compared to SRL 
(figure 7.1A and B).No increasing IC50 values and significant differences in IC50 
values were observed when CsA was used in combination with SRL and EVL 
(figure 7.1C and D). 
 
CN inhibition by CNIs, MTIs and combinations thereof 
To further investigate the origin of the observed IL-2 antagonism, we measured 
calcineurin activity that is the pharmacological target enzyme of TRL. First, the 
individual effect of the immunosuppressants on CN activity was investigated and 
therefore CN inhibition curves were determined for CsA, TRL, EVL and SRL. The 
data in Figure 7.2 show that SRL and EVL do not inhibit CN activity, while for TRL 
and CsA a clear dose– response curve was found with an IC50 value of 1.0 µg/L 
(0.51– 2.1 µg/L, 95% CI) and an Emax of 53% (48–58%, 95% CI) for TRL and an 
IC50 value of 14 µg/L (9.6–21 µg/L, 95% CI) and an Emax of 31% (26–36%, 95% CI) 
for CsA.  
 
Figure 7.2. CN inhibition by CsA, TRL, SRL and EVL. Data are normalized and expressed as % by 
dividing through CNI blank measurement (performed in quadruple) and maximum effect was fixed at 
100% for the sigmodial dose–response analysis in GraphPad. Data are presented as mean of duplicate 
measurement. 
 
Next, we incubated five concentrations of TRL (0.0625–625 µg/L) and a TRL blank, 
each in combination with five concentrations (0.25–2500 µg/L) and a blank of either 
EVL or SRL. As control experiment TRL was replaced by CsA (0.25– 2500 µg/L). 
The obtained CN inhibition curves are shown in figure 7.3 and the calculated IC50 
concentrations for TRL and CsA in the presence of various concentrations of EVL 
and SRL are listed in table 7.2.  
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Figure 7.3. CN inhibition by CsA and TRL in the presence of MTIs. CN inhibition by TRL was 
determined in the presence of SRL  (A) and EVL (B). (C) and (D) show the CN inhibition by CsA in the 
presence of the same concentrations of SRL and EVL respectively. Data show the mean of duplicate of 
one healthy individual and the lines are the CN inhibition curves of TRL and CsA in the presence of 
various concentrations of EVL and SRL fitted for sigmodial dose–response curves by GraphPad 
software. The IC50 values for CsA and TRL obtained from these curves are listed in table 7.2. Data were 
normalized by dividing through blank measurement in the absence of CNI and MTI. CNI 0 values were 
set at 10
-4
 µg/L for the regression analysis. 
 
 
  [mTOR inhibitor] Tacrolimus Cyclosporin A 
  in µg/L IC50 in µg/L (95% CI) IC50 in µg/L (95% CI) 
Sirolimus 0 1.0 (0.32 - 3.4) 30 (12 - 74) 
 0.25 1.5 (0.69 - 3.4) 13 (7.8 - 23) 
 2.5 3.8 (1.6 - 8.8) 31 (15 - 63) 
 25 11 (6.7 - 18) 29 (11 - 79) 
 250 125 (25 – 620) 13 (5.3 - 31) 
  2500 290 (0.08 - 1.1·10
6
) 16 (8.5 - 31) 
Everolimus 0 0.54 (0.15 – 1.9) 14 (5.1 - 41) 
 0.25 0.70 (0.34 – 1.4) 7.6 (3.7 - 16) 
 2.5 1.2 (0.39 - 3.9) 13 (4.0 - 43) 
 25 4.6 (0.91 – 23) 11 (5.2 - 23) 
 250 20 (3.7 - 104) 7.1 (4.0 - 13) 
  2500 320 (0.21 - 5.0·10
5
) 13 (9.8 - 17) 
 
Table 7.2. CN IC50 values of TRL and CsA in the presence of various concentrations of SRL and 
EVL. IC50 values and 95% confidence intervals (CI) were obtained from the sigmoidal concentration–
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A concentration dependent effect of EVL and SRL on CN inhibition by TRL was 
observed and significant higher TRL IC50 values were found when 25 µg/L SRL 
and 250 mg/L EVL or higher, were present in culture medium (figure 7.3A and B). 
This pattern was not detected for the CsA CN inhibition curves; here no differences 
in IC50 values were observed by increasing concentration of MTIs (figure 7.3C and 
D). 
 
Antagonism of MTIs on TRL based immune suppression in 10 healthy 
volunteers 
To determine whether the TRL/MTI interactions are reproducible for other 
individuals we investigated the interaction on PBMCs isolated from 10 healthy 
volunteers. For reproduction of the immunological antagonism we reproduced the 
experiment for 10 healthy volunteers and treated the PBMCs with 0.625 
µg/LTRLand 25 µg/L ofEVL orSRL, concentrations that previously (figure 7.1) 
showed to be characteristic for the interaction. The results are shown in figure 7.4.  
 
Figure 7.4. MTI antagonism in 10 healthy volunteers. Left: IL-2 excretion after PHA/PMA stimulation 
for combinations of TRL (0.625 µg/L TRL) and MTIs (25 µg/L). Right: CN activity in the 
presence/absence of 6.25 µg/L TRL, and 25 µg/L EVL or SRL. Both were tested on PBMCs isolated 
from 10 healthy volunteers and data were normalized to remove inter-individual variation in absolute IL-
2 excretion and CN activity. Data are presented as mean W SEM and statistical significance was tested 
using paired Student t-tests and presented as (***) for P < 0.001 and (**) for P < 0.01. 
 
All three drugs inhibited IL-2 excretion in our cell culture system, though TRL 
caused a larger inhibition than SRL (P = 0.001) and EVL (P = 0.002) that partially 
inhibited the IL-2 excretion in these concentrations. When combinations of TRL and 
MTIs were tested, SRL significantly reversed IL-2 excretion inhibition by TRL (P = 
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concentrations observed for the EVL/TRL combination was also significant lower 
when compared to the combination of SRL/TRL (P = 0.01).  
Next, we determined CN activity in the presence/absence of TRL (6.25 µg/L) 
and/or EVL/SRL (25 µg/L), concentrations that were previously illustrative for the 
interaction (figure 7.3).  
Here no CN inhibition was found for SRL and EVL. TRL caused a mean CN 
inhibition of 44 ± 11% (SD) in the PBMC fractions isolated from these individuals. 
When MTIs were co-incubated with TRL in the culture medium, CN inhibition by 
TRL was partially lost and final mean inhibition in the presence of SRL and EVL 
was 18 ± 14% and 26 ± 10%, respectively. Both were significant lower (P < 0.001) 
when compared to TRL alone. Antagonism of SRL on TRL mediated CN inhibition 
was significantly larger than that of EVL for these concentrations (P = 0.01). 
 
Role of FKBPs 
To investigate whether the mechanism of antagonism between both mTOR 
inhibitors and TRL was mediated via competition for saturated FKBP binding sites, 
we prepared PBMC lysate from untreated cells of 4 healthy volunteers in duplicate 
and incubated (1 h, 37 °C) these with and without mTOR inhibitor, TRL and 
FKBP12. CN activity was determined directly after incubation. The results of these 
experiments are shown in figure 7.5.  
 
Figure 7.5. CN activity after FKBP12, TRL and MTI addition to cell lysate. CN activity was 
determined in PBMC lysate in the presence/absence of TRL, FKBP12 and either SRL or EVL and 
expressed as % of blank measurement. Final concentrations were 25 µg/L TRL, 50 µg/L of SRL/EVL 
and 0, 2000 and 10000 µg/L of FKBP12 was added to cell lysate. Results were obtained from duplicate 
measurement of 4 healthy volunteers and presented as mean W SEM. Statistical analysis were 
performed between TRL and TRL + SRL or EVL conditions, except when lines indicate otherwise and 
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In this test system no inhibition of CN was found by the MTIs, FKBP12 and 
combinations thereof (data not shown). Inhibition by TRL in cell lysate was 
observed though it was much smaller (±10%) compared to the cell systems. Since 
the addition of 2000 µg/L FKBP12 increased TRL inhibition (±35%, P < 0.001) it 
seemed that the FKBP12 pool from the intracellular compartment was diluted in the 
cell lysate, limiting CN inhibition by TRL. Addition of SRL to TRL reduced TRL 
inhibition of CN (P = 0.005), while for EVL antagonism under these conditions 
could not be detected (P = 0.7). In the presence of 2000 µg/L FKBP12 antagonism 
for both SRL and EVL was found (for both P < 0.001) and when 10000 µg/L 





In transplant recipients, multiple immunosuppressive agentsare normally used in 
order to optimally prevent acute rejection episodes and to reduce the side effects of 
the individual drugs(1). The CNI and MTI class of drugs require intracellular binding 
proteins (immunophilins) to exert their immunosuppressive action. TRL binds to its 
intracellular binding proteins (FKBPs) and especially the 12 kDa protein FKBP12 is 
considered critical for the immunosuppressive action of TRL(14). The MTIs SRL 
and its analog EVL require binding to the same protein though an other 
immunosuppressive mechanism is observed for these drugs(6,15). Where TRL 
inhibits CN and block T-cell receptor induced activation/proliferation of Tcells, the 
mTOR inhibitors inhibit IL-2 induced T-cell proliferation(7,15). In this study, using a 
CN assay, we confirmed that CN enzyme activity is not inhibited by EVL and SRL 
but selectively by TRL and CsA (figure 7.2), which is in agreement with previous 
observations.  
In studies by Dumont et al., reciprocal antagonism was observed for SRL and TRL 
which was explained by the use of similar intracellular binding sites of the 
drugs(5,8). Here we show that both SRL and EVL antagonize TRL mediated CN 
inhibition and TRL inhibition of IL-2 excretion in PHA/PMA stimulated PBMCs, an 
effect which is not observed for the CNI CsA. In addition, we show that the 
antagonism between MTIs and TRL in cell lysate is reversed by the addition of 
excess of FKBP12 (10000 µg/L), indicating that the antagonism is mediated via this 
protein. The in vitro antagonism observed in our cellular system is significant 
starting at SRL concentrations of 25 µg/L for CN activity and 250 µg/L for IL-2 
excretion and at EVL concentrations of 250 µg/L for both CN inhibition and IL-2 
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excretion inhibition by TRL. These relative high concentrations of MTIs in 
combination with TRL seem to saturate FKBP binding sites that are required for CN 
inhibition by TRL. Competition between the MTIs and TRL for these binding sites is 
clearly illustrated by the IL-2 interaction experiments in figure 7.1. Here it is shown 
that 0.625 µg/L TRL itself inhibits IL-2 excretion, but when increasing 
concentrations of SRL are introduced, above a certain threshold (25 µg/L SRL), IL-
2 inhibition by TRL is lost and the IL-2 response is more comparable to the 25 µg/L 
SRL response itself. 
The MTIs themselves reduce IL-2 excretion in our cell culture system, without 
showing a clear sigmoidal concentration– response relationship. This effect is 
probably best explained to be indirect and mediated through inhibition of 
proliferation/activation of IL-2 producing cells. In our system the lowest MTIs 
concentrations used already significantly decreased IL-2 excretion. Under these 
conditions of low MTI concentration, immunosuppressive additivity or even 
synergism could be very well achieved in patients in combination protocols with 
CsA, but also TRL; although MTIs are mechanistically antagonists of TRL, 
antagonism only occurs at saturating conditions for FKBP. Immunosuppressive 
synergy has been demonstrated for SRL/TRL and SRL/CsA combinations on 
lymphocyte proliferation and lymphocyte activation markers(10).  
25 µg/L of both EVL and SRL partially reversed CN inhibition by 6.25 µg/L TRL 
though the interference by SRL was significant larger when compared to EVL in 10 
healthy volunteers. In addition, only SRL could significantly reverse IL-2 inhibition 
by 0.625 µg/L TRL. These results indicate relevant differences between both MTIs 
that could be explained by the weaker binding of EVL to FKBP12(6).  
Kung and Halloran showed that at high concentrations of CNIs, immunophilins limit 
CN inhibition for both CsA and TRL(16). It is however not known whether this is 
relevant for CNI treated patients. When using combination immunosuppressant 
therapy of both MTI and TRL, saturation of FKBPs and thus pharmacological drug–
drug interaction is even more likely and this interaction could therefore be clinically 
relevant. The MTI concentrations for which TRL antagonism was observed (25 
µg/L) are of the same magnitude of MTI blood concentrations in allograft recipients 
treated with these drugs(17). In addition, also the TRL concentrations at which the 
interference was observed are found in allograft recipients treated with this 
drug(17). The drug concentrations that are used in our in vitro model can however 
not directly be translated to full blood drug concentrations, since drug 
concentrations from cell culture experiments do not necessarily show similar 
cellular responses compared to drug concentrations in blood due to the presence 
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of irrelevant binding sites as has been demonstrated for CsA(18). The true clinical 
relevance remains therefore unclear.  
If CN inhibition is limited by the immunophilin content in patients receiving CNI, this 
could be of great importance; higher CNI concentrations are ineffective. Especially 
early after graft implantation, when the blood concentrations are highest, this might 
become relevant. Consequently, under condition of immunophilin saturation, inter-
individual variation in the content of immunophilins could be of great importance for 
allowing different maximal CN inhibitions. 
Finally, blood drug concentrations and also intracellular drug concentrations are not 
able to detect the limitation of CN inhibition by immunophilins. Only 
pharmacodynamic strategies are theoretically capable of detecting these. This also 
holds for detecting the interaction between the MTI and TRL in individuals receiving 
both drugs.  
In conclusion, it is shown that mTOR inhibitors can antagonize TRL and not CsA 
mediated immunosuppression. FKBP12 that is bound by EVL and SRL, and 
required for TRL based CN inhibition is a key mediator; saturation of this protein by 
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Over the last decades, restoration of renal function by renal allograft 
transplantation has evolved into the preferred treatment option for patients with end 
stage renal disease. The introduction of the calcineurin inhibitors (CNI) 
cyclosporine (CsA) and tacrolimus (TRL) have significantly contributed to this 
success. Both CNIs allowed successful suppression of the immunological response 
and rejection of the allograft by the recipient(1). Unfortunately considerable 
adverse drug effects are observed in patients treated with CNIs, including 
nephrotoxicity, hypertension and diabetes mellitus(2-4). This, together with the 
large inter-individual variation in pharmacokinetics of both drugs necessitates 
therapeutic drug monitoring (TDM) to control drug exposure(5). Nowadays, TDM of 
CNI is routinely performed by drug concentration measurement in blood which has 
led to an improved clinical performance of these drugs. Though acute rejection 
episodes have been significantly reduced, the incidence of acute allograft rejection 
episodes is still 10-20% within first year after transplantation(6). In addition, lack of 
selectivity and over-immunosuppression, at least partly caused by CNIs, hampers 
long-term allograft and patient survival. CNI withdrawal and avoidance protocols 
have been investigated with varying results. Early removal of CNIs from the 
immunosuppressive protocols continues to be problematic mainly due to the 
occurrence of late acute rejection(7,8). Minimization of CNIs in the 
immunosuppressive protocols early after transplantation was recently found to be 
equally effective as compared to the “old standards” with higher CNI target 
concentrations(9). 
Another strategy to improve clinical immunesuppresion early after transplantation is 
improved monitoring to control CNI therapy. TDM for CNI treatment is mandatory 
since there is a clear relation between drug exposure and incidence of acute 
rejection and drug toxicity(10,11). Improvement of CNI therapy by better monitoring 
is an interesting strategy, since in current daily practice TDM is performed under 
suboptimal monitoring conditions. This includes TDM by through drug 
concentrations (C0) and non-standardized sampling protocols. Next to advanced 
pharmacokinetic monitoring, such as estimated AUC monitoring, the development 
of pharmacodynamic (PD) markers could theoretically contribute to improve CNI 
therapy. Pharmacodynamic monitoring strategies, however, are still in an 
experimental phase and have not proven clinical benefit yet. They carry the 
theoretical advantage of monitoring the true effectiveness of immunosuppressive 
therapy including CNIs. In addition, pharmacological and immunological drug-drug 
interaction can be detected. This led us to investigate PD monitoring as potential 




tool to guide drug dosing. We choose CN activity as PD marker for monitoring and 
in this thesis, the analytical aspects, fundamental characteristics and insights in 
clinical usefulness of CN activity measurement as a PD marker for CNI were 
investigated. 
 
(Bio) analytical aspects of CN enzyme activity measurement 
As starting point to research PD monitoring of CN inhibition therapy a CN enzyme 
activity assay was developed (Chapter 2). CN activity was determined in the 
leukocyte fraction isolated from peripheral blood. CN activity was determined by 
phosphate quantification after dephosphorylation of the phosphorylated RII 
substrate. Phosphate concentration was determined using the malachite green 
phosphate reagent. To adjust for background absorbance, a blank measurement 
without substrate was included. Ascorbic acid, NP-40 and DTT were titrated in the 
lysis buffer that resulted in a significant increase in CN activity and conservation of 
CN activity during sample storage. This was hypothized to be caused by prevention 
of CN oxidation that is known to be enzymatically inactivated by oxidation(12,13). 
Furthermore CN inhibition by both TRL and CsA was found in vitro as well as in 
renal allograft recipients treated with either TRL or CsA.  
In Chapter 3 we investigated the relation between CN inhibition, inhibition of T cell 
cytokine excretion and their relation at therapeutic CsA concentrations. Blood from 
healthy volunteers incubated with relevant high range CsA concentrations (2500 
µg/L) showed only a minor increase in CN inhibition when CsA was added in 
excess (25000 µg/L). In addition, no increase in cytokine excretion after CD3/CD28 
stimulation was observed. This indicated that in the system used, at 2500 µg/L, 
CsA approaches immunosuppressive saturation. At relevant target C0/C2 levels 
early and late after renal transplantation (100, 250, 600 and 1700 µg/L) every 
condition represented a distinct immunosuppressive state. In addition after an initial 
CN inhibition threshold, small increases in CN inhibition resulted in relatively large 
changes in T cell cytokine excretion. No cyclophilin limitation at 2500 µg/L CsA 
could be detected. These results showed that CN activity could act as a relevant 
marker to monitor CsA based immunosuppression. 
As a follow-up, we investigated whether the leukocyte fraction is a representative 
matrix for monitoring CsA therapy by CN activity measurement in renal allograft 
recipients. This is described in Chapter 4. Large inter-individual variation in CN 
activity was observed in renal allograft recipients receiving CsA. In addition, large 
variation in sample composition was observed when parallel to CN activity, 




leukocyte concentrations of granulocytes, monocytes and lymphocyte subsets 
including T cells B cells and NK cells in peripheral blood were determined. Next, 
cell specific CN activities and CsA inhibition curves were determined and revealed 
cellular differences in CN activity. Similar cellular differences have been observed 
previously(14). No clear deviations in CsA inhibition profiles for the different 
leukocyte subsets were observed as has been described before(15). Altogether, 
these results could indicate that sample composition, at least partially, determines 
CN activity measurement outcome. When applying CN activity monitoring in clinical 
practice CN activity could therefore be biased by sample composition. Interestingly, 
the sample composition effect could also be relevant for other PD markers used 
such as mRNA transcripts or cytokines excretion markers. Here T cell specific 
mRNA transcripts isolated from the mononuclear cell fraction are used as readout 
and expressed against reference transcripts available in all mononuclear cells(16-
18). Variation in relative T cell concentration between and within individuals could 
therefore confound these markers in a similar way. An interesting next step would 
be to monitor specifically in the target compartment(s) of CNI; the T cells. T cell 
specific readout assays could eliminate the compositional effects on measurement 
outcome and in addition, monitor in the immunological relevant cells(19,20).  
To anticipate on the suggested higher specificity of T cell specific 
pharmacodynamic assays, we have developed a T cell specific CN assay for 
monitoring CsA therapy (Chapter 6). In this protocol T cells were isolated from 
peripheral blood using paramagnetic beads coated with anti-CD3 antibodies. T 
cells isolates from peripheral blood were highly pure 95% ± 1.5% and showed to be 
a representative sample of whole blood T cells, since no differences in CD4+ and 
CD8+ subsets were found. When coupled to the CN activity assay protocol, 
adequate analytical performance was observed and no washing out of CsA during 
sample preparation. In addition, in 6 renal allograft recipients receiving CsA 
therapy, inhibition of T cell specific CN activity was observed. In future studies it 
would be very interesting to investigate the relevance of the T cell specific 
calcineurin activity marker as tool for monitoring CsA therapy. Measurement of 
other intracellular T cell markers such as protein concentrations or their activities, 
drug concentrations and metabolic compounds could be very relevant markers for 
a large variety of diagnostic fields.   
 
Fundamental properties of PD strategies 
To gain insights in the current status of PD monitoring for CNI therapy, a review of 




recent literature on this subject was performed (Chapter 5). Two different types of 
PD monitoring strategies have been investigated. The first type monitors enzyme 
activity and the second cellular responsiveness after in vitro stimulated 
immunological responses. CN activity has been measured in various cellular 
fractions such as whole blood, leukocytes and peripheral blood mononuclear cells 
(PBMC) and is usually performed in conditions of co-reagent excess. It is therefore 
more appropriate to refer to as CN capacity measurement. For immunological 
strategies simulation of immunological responses is performed by mitogen or 
CD3/CD28-directed T cell activation. Immune responsiveness has been 
investigated at several levels such as mRNA transcripts, (intracellular) 
concentration/excretion of cytokines, expression of surface activation markers and 
cell proliferation. So far, clear relations of such markers with drug concentrations 
have been observed, but no definite clinical benefits have been reported(19,21,22). 
The large inter-individual variation of pharmacodynamic marker outcome could not 
been explained by clinical end-points such as acute rejection. Better insight in the 
large inter-individual variation is relevant to understand and further develop new, 
more accurate markers. Strategies including pharmacodynamic parameters have 
proven to be valuable in studying pharmacological drug-drug interactions of 
combinational immunosuppressive therapy applied in allograft recipients and 
visualizing in vivo immunosuppression(23-26).  
We have used pharmacodynamic strategies to investigate the drug-drug interaction 
between TRL and the mTOR inhibitors sirolimus (SRL) and everolimus (EVL) 
(Chapter 7). Combinational therapies including mTOR inhibitors are increasingly 
applied in allograft recipients. However, based on the pharmacological mechanism 
of mTOR inhibition by the mTOR inhibitors and CN inhibition by TRL, 
pharmacological interactions can be expected. Both drugs bind to FK-binding 
proteins and complexes of either FK-binding protein with TRL or mTOR inhibitor 
selectively inhibit CN and mTOR respectively(27-29). We have tested the effect of 
the mTOR inhibitors SRL and EVL on TRL based CN inhibition in PBMC cell 
cultures. First, no CN inhibition was observed for both SRL and EVL. Next 
combinations of mTOR inhibitor with TRL led to increased TRL IC50 values for CN 
activity as well as IL2 excretion after mitogen stimulation. This was reproduced in 
10 healthy volunteers. No antagonism was observed for CsA, which does not 
require FKBPs for CN inhibition. When FKBP12 was added to cell lysates TRL 
antagonism by SRL and EVL could be reversed. Altogether, these results indicate 
that competition for FKBP binding sites mediates the antagonism. Since all 




experiments have been performed in culture conditions, the clinical relevance of 
the antagonism remains unknown. Due to the presence of irrelevant binding sites 
in whole blood that are absent in culture medium extrapolation of culture 
concentrations is required, as has been demonstrated for CsA(30). It would be very 
relevant to investigate whether this antagonism occurs under relevant in vivo blood 
concentrations of mTOR inhibitors and TRL.  
 
Overall conclusions and future perspectives 
This thesis shows that pharmacodynamic monitoring strategies, including CN 
activity, are very helpful in describing immunosuppressive responses and 
interactions. Especially in well controlled in vitro experimental set-ups these assays 
can be used to investigate drug properties and interactions. CN activity was very 
useful to illustrate the pharmacological and immunological interaction of TRL with 
the mTOR inhibitors SRL and EVL. This rate limiting interaction is mediated via 
competition for the relevant chaperone for both drug classes. A relevant follow-up 
would be to investigate the clinical relevance of this interaction.   
Unfortunately, the pharmacodynamic monitoring strategies are not ready yet for 
clinical use as marker to guide drug dosing. For the final transition from 
investigative tools to relevant biomarkers, insight in the analytical and biological 
variables appears to be of key importance. We have illustrated the importance of 
sample/matrix choice. Confounding of measurement outcome by sample 
composition should be avoided or at least adjusted for. Specific measurement in 
the relevant pharmacological and immunological target compartments of CNI to 
evade from these methodological confounders.     
In this respect we have developed a T cell specific CN assay that showed 
acceptable analytical performance. T cell specificity could also contribute to 
improved performance of other pharmacodynamic markers for monitoring CNI 
therapy such as T cell specific cytokines, mRNA and cell surface T cell activation 
markers. This could be performed by for instance T cell specific stimulation and 
includes the activation of T cells by targeting specific T cell epitopes e.g. CD3 and 
CD28. In such assays, optimization of the time interval should prevent secondary 
activation of other cells present due to cytokines produced by activated T cells. 
Finally, T cell specific assays to asses T cell specific CN activity need to be 
validated as a marker for monitoring CsA therapy in a large cohort of patients 
treated with CNIs in order to proof their clinical relevance.  
This thesis has demonstrated that the anticipation on analytical confounders, such 




as sample choice, is crucial for the development of CN activity as a marker that has 
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Bij orgaan transplantatie patiënten is een goede onderdrukking van de 
immunologische reactie tegen het ontvangen, lichaamsvreemde orgaan van 
cruciaal belang. Om deze natuurlijke afstotingsreactie te onderdrukken wordt 
immuunsuppressieve therapie gebruikt. Als deze niet gegeven wordt, of niet 
toerijkend is, stoot het lichaam het ontvangen orgaan af. Dit betekent dat het 
lichaam het ontvangen orgaan vernietigd.  
Er zijn verschillende medicijnen die gebruikt kunnen worden als 
immuunsuppressieve therapie. Kort na transplantatie vormt een zogenaamde 
calcineurine (CN) remmer de basis van de immuunsuppressieve therapie. Er zijn 2 
calcineurine remmers in gebruik in de transplantatie geneeskunde; tacrolimus 
(TRL) en ciclosporine (CsA). Deze calcineurine remmers zorgen voor een goede 
onderdrukking van de afstotingreactie, maar kunnen ernstige bijwerkingen geven, 
waaronder niertoxiciteit, hoge bloeddruk en suikerziekte. Een ander probleem van 
TRL en CsA therapie is dat er grote verschillen tussen personen bestaan in de 
mate waarop deze medicijnen worden opgenomen in, of uitgescheiden door, het 
lichaam. De mate waarin een individu TRL of CsA opneemt of uitscheidt is van te 
voren moeilijk te voorspellen, terwijl een minimale aanwezigheid van CsA of TRL 
noodzakelijk is voor een goede onderdrukking van het immuunsysteem en een te 
grote aanwezigheid kan zorgen voor ernstige bijwerkingen. Om de aanwezigheid 
van CsA of TRL te controleren worden medicijnconcentraties in het bloed gemeten. 
Deze zijn een maat voor de aanwezigheid van CsA of TRL in het lichaam. Bij te 
lage CsA of TRL concentraties wordt vervolgens de medicijn dosis verhoogd en bij 
te hoge concentraties wordt de medicijn dosis verlaagd. Dit zogenoemde 
farmacotherapeutisch monitoren zorgt dat de blootstelling aan CsA en TRL binnen 
vastgestelde grenzen blijft. 
Ondanks dat calcineurine remming therapie op deze manier gecontroleerd wordt, 
komen er nog steeds afstotingsreacties voor en vormt de medicijn toxiciteit naast 
over-immuunsuppressie een groot klinisch probleem. Het beter meten van CsA en 
TRL therapie in de patiënt zou voor een verdere verbetering van de calcineurine 
remmings therapie kunnen zorgen. De therapie kan dan beter ingesteld worden, 
waardoor er minder afstotingsreacties en bijwerkingen optreden. Dit kan gedaan 
worden door geavanceerde strategieën te gebruiken zoals het schatten van de 
totale medicijn blootstelling op basis van meerdere concentratie bepalingen na 
inname (AUC waarden), of het implementeren van farmacogenetica. Bij 
farmacogenetica kan aan de hand van het genetisch profiel van een persoon een 
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inschatting worden gemaakt van de opname en uitscheiding van CsA en TRL. 
Daarnaast kan er gedacht worden aan monitorings strategieën waarbij men de 
werking van CsA of TRL meet. Dit wordt ook wel farmacodynamisch monitoren 
genoemd. De medicijn concentraties zijn wel gecorreleerd aan de werking die ze 
hebben, maar zijn slechts een indirecte maat. Helaas is het zo dat 
farmacodynamische monitorings strategieën nog in een experimentele fase zitten 
en dat ze klinisch nog geen bewezen toegevoegde waarde hebben. Dit heeft ons 
ertoe bewogen om de toepassing van deze markers voor het monitoren van CsA 
en TRL therapie bij orgaantransplantatiepatiënten te onderzoeken. Hierbij hebben 
wij ons vooral gericht op de calcineurine activiteit als farmacodynamische marker. 
 
Om de werking van de calcineurine remmers TRL en CsA te meten werd er een 
calcineurine activiteits meting ontwikkeld. Deze staat beschreven in hoofdstuk 2. 
Met deze methode (assay) wordt de calcineurine activiteit in de witte bloedcellen 
gemeten. Er werd voor de witte bloedcel fractie van het bloed gekozen omdat 
calcineurine remming in deze cellen zorgt voor immuunsuppressie. In de assay 
wordt het RII substraat specifiek door calcineurine omgezet in vrij fosfaat. De 
hoeveelheid vrijgekomen fosfaat wordt gemeten met het malachite green 
kleurreagens. De hoeveelheid fosfaat dat vrij komt in een bepaalde tijd is 
vervolgens een maat voor de calcineurine activiteit. De assay liet een goede 
reproduceerbaarheid, lineariteit en calcineurine remming door CsA en TRL zien. 
Tot slot werd aangetoond dat de calcineurine activiteit geremd wordt in 
niertransplantatie patiënten die CsA of TRL therapie ontvangen. 
 
In een vervolg studie werd gekeken of de calcineurine activiteit daadwerkelijk een 
maat is voor de immuunsuppressie bij patiënten die behandeld zijn met CsA. Dit 
staat beschreven in hoofdstuk 3. Er werd gevonden dat verschillende 
therapeutische CsA concentraties een verschillende onderdrukking van de 
calcineurine activiteit lieten zien. Dit gold ook voor IFNγ en TNFα secretie na T cel 
specifieke stimulatie. Deze laatste twee zijn stoffen die bij een immuunreactie 
vrijkomen uit de witte bloedcellen. Dit betekent dat zowel de calcineurine activiteit 
als cytokine excretie na T cel specifieke stimulatie in staat zijn om de werking van 
CsA therapie bij relevante CsA concentraties te laten zien. 
 
Er zijn meerdere klassen van witte bloedcellen, waaronder lymfocyten, 
granulocyten en monocyten. Deze hebben ieder een andere rol bij de 
afweerreactie. De concentratie van deze cellen in het bloed kan behoorlijk variëren. 
Om de keuze voor de witte bloedcelfractie als monster voor de calcineurine assay 
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te evalueren werd gekeken wat het effect is van een samenstellingsverandering 
van de witte bloedcel fractie op de gemeten calcineurine activiteit. Dit staat 
beschreven in hoofdstuk 4. Dit werd gedaan door bij 25 
niertransplantatiepatiënten naast de calcineurine activiteit, tegelijkertijd de 
leukocyten-samenstelling te bepalen. Bij deze patiënten was er een grote spreiding 
in de calcineurine activiteit en samenstelling van de leukocyten fractie zichtbaar. 
De celspecifieke CN activiteit van de individuele witte bloedcel soorten liet ook 
duidelijke verschillen zien. Zo bleken monocyten een hogere CN activiteit te 
hebben dan bijvoorbeeld lymfocyten. Dit zou kunnen betekenen dat bij patiënten 
met relatief veel monocyten er een hogere calcineurine activiteit gevonden kan 
worden, niet op basis van de activiteit, maar op basis van de aanwezigheid van 
relatief meer monocyten. Deze problematiek kan omzeild worden door specifiek in 
die celfractie te meten waar de CsA en TRL hun therapeutische effect genereren; 
de T lymfocyt. 
 
Naast de door ons ontwikkelde calcineurine assay zijn er verschillende methoden 
beschikbaar om naar het effect van immuunsuppressieve medicatie en in het 
bijzonder de calcineurine remmers te kijken. Deze verschillende technieken staan 
beschreven in hoofdstuk 5. Er zijn 2 verschillende methoden beschreven. 1) 
methoden die de activiteit van het directe doeleiwit meten en 2) technieken die 
immunologische waarden meten na het nabootsen van een T cel respons. Bij het 
eerste type wordt de calcineurine activiteit bepaald. Hiervoor zijn verschillende 
methoden beschreven. Deze verschillen in de manier waarop de calcineurine 
activiteit wordt gedefinieerd, het monster waarin de activiteit wordt gemeten en de 
detectie techniek die wordt gebruikt. Meting van het directe enzym heeft als 
voordeel dat andere soorten immuunsuppressieve medicatie geen direct effect 
hebben op de meting. Bij het tweede type, worden witte bloedcellen, of specifieker 
T cellen, gestimuleerd en wordt de reactie van de cel als uitleesmaat genomen. 
Deze wordt uitgelezen aan de hand van signaal moleculen die de geactiveerde 
cellen uitscheiden of tot expressie brengen zoals mRNA transcripts, cytokinen, 
oppervlakte eiwitten en cel deling. Deze methoden kunnen ook effecten van 
andere klassen van immuunsuppressieve medicatie laten zien. Helaas is er nog 
geen duidelijke marker die in patiënten een duidelijke relatie laat zien tussen meet 
waarde en klinische parameters van immuunsuppressie of calcineurine remmer 
toxiciteit. Meer inzicht in de grote inter-individuele variatie lijkt noodzakelijk voor de 
ontwikkeling van geschikte markers voor het farmacodynamisch monitoren van 
CsA en TRL therapie.  
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Voor het ontwikkelen van een specifiekere marker voor het monitoren van CsA en 
TRL therapie is er een T cel specifieke calcineurine assay opgezet Deze methode 
staat beschreven in hoofdstuk 6. De methode maakt gebruikt van microkraaltjes 
waarop antistoffen tegen de T cel zitten. Deze kraaltjes worden in een magnetisch 
veld magnetisch en hiermee kunnen de T cellen uit het bloed worden 
weggevangen. De geïsoleerde T cellen worden vervolgens verder verwerkt 
volgens de eerder ontwikkelde calcineurine assay. De methode liet een goede 
zuiverheid van T cellen en goede analytische eigenschappen zien. Daarnaast werd 
er in zes patiënten die CsA kregen, T cel specifieke calcineurine remming 
gevonden. Het zou nu zeer relevant zijn om met deze methode de calcineurine 
activiteit in T cellen van transplantatiepatiënten te monitoren die worden behandeld 
met CsA. 
 
Tot slot werd gekeken of er met farmacodynamische monitorings technieken 
medicijn interacties kunnen worden opgepikt (hoofdstuk 7). Hiervoor werden de 
witte bloedcellen geïsoleerd uit bloed van bloeddonoren van de bloedbank. Deze 
cellen werden geïncubeerd met verschillende TRL, everolimus en sirolimus 
concentraties en vervolgens werd de farmacologische interactie tussen TRL en de 
mTOR remmers sirolimus en everolimus bestudeerd. Alle drie de medicijnen 
binden aan het eiwit FKBP wat nodig is voor hun werking. Bij combinatie therapie 
van deze medicijnen zou er verzadiging kunnen zijn van FKBP bindingsplaatsen 
waardoor er competitie en verdringing kan optreden. Calcineurine activiteit en de 
excretie van cytokinen na witte bloedcel stimulatie werden gebruikt als uitleesmaat. 
Er werd gevonden dat hoge concentraties van everolimus of sirolimus de 
calcineurine remming van TRL teniet konden doen. Dit betekende dat 
combinatietherapie van een mTOR remmer met TRL bij hogere concentraties een 
ongunstige immuunsuppressieve respons liet zien. Of dit klinisch relevant is was 
echter niet vast te stellen, omdat deze experimenten zijn uitgevoerd in kweek 
media en de medicijnconcentraties hierin niet vergelijkbaar zijn met dezelfde 
concentraties in bloed. Het zou echter erg relevant zijn om dit uit te zoeken.  
 
Samengevat laat dit proefschrift zien dat de calcineurine activiteit geschikt is als 
marker voor het bestuderen van TRL en CsA. Voor het gebruik van calcineurine 
activiteit als marker voor het monitoren van transplantatiepatiënten is verder inzicht 
in de analytische en biologische variatie nodig. Deze kan dan gebruikt worden voor 
het ontwikkelen van calcineurine assays die klinisch toegevoegde waarde hebben. 
De ontwikkelde T cel specifieke calcineurine activiteits assay is een interessante 
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